Contingent cardio-protection for epilepsy patients

Description

BACKGROUND OF THE INVENTION

This invention relates generally to medical devices, and, more particularly, to methods, apparatus, and systems for performing vagus nerve stimulation (VNS) for treating epileptic seizures characterized by cardiac changes, including ictal tachycardia.

DESCRIPTION OF THE RELATED ART

While seizures are the best known and most studied manifestations of epilepsy, cardiac alterations are prevalent and may account for the high rate of sudden unexpected death (SUDEP) in these patients. These alterations may include changes in rate (most commonly tachycardia, rarely bradycardia or asystole), rhythm (PACs, PVCs,), conduction (e.g., bundle branch block) and repolarization abnormalities (e.g., Q-T prolongation, which occurs primarily during (ictal) but also between (inter-ictal) seizures). In addition, S-T segment depression (a sign of myocardial ischemia) is observed during epileptic seizures. Significant elevations in heart-type fatty acid binding protein (H-FABP), a cytoplasmic low-molecular weight protein released into the circulation during myocardial injury have been documented in patients with epilepsy and without evidence of coronary artery disease, not only during seizures but also during free-seizure periods. H-FABP is a more sensitive and specific marker of myocardial ischemia than troponin I or CK-MB. Elevations in H-FABP appear to be un-correlated with duration of illness, of the recorded seizures, or with the Chalfont severity score of the patients.

The cardiac alterations in epilepsy patients, both during and between seizures, have a multi-factorial etiology, but a vago-sympathetic imbalance seems to play a prominent role in their generation. The majority of epileptic seizures enhance the sympathetic tone (plasma noradrenaline and adrenaline rise markedly after seizure onset) causing tachycardia, arterial hypertension and increases in the respiratory rate, among others. Recurrent and frequent exposure to the outpouring of catecholamines associated with seizures in patients with pharamaco-resistant epilepsies may, for example, account for abnormalities that increase the risk of sudden death such as prolongation of the Q-T interval which leads (often fatal) tachyarrhythmias such as torsade de pointe. Further evidence in support of the role of catecholamines in SUDEP is found in autopsies of SUDEP victims, revealing interstitial myocardial fibrosis (a risk factor for lethal arrhythmias), myocyte vacuolization, atrophy of cardiomyocytes, leukocytic infiltration, and perivascular fibrosis. Restoration of the sympatho-parasympathetic tone to normal levels, a therapeutic objective that may be accomplished by enhancing para-sympathetic activity though among others, electrical stimulation of the vagus nerve, may decrease the rate and severity of cardiac and autonomic co-morbidities in these patients.

While there have been significant advances over the last several decades in treatments for epileptic seizures, the management of co-morbidities—in particular the cardiac alterations associated with seizures—remains largely unaddressed. There is a need for improved epilepsy treatments that address cardiac impairments associated with seizures. Pharmacological therapies for neurological diseases (including epilepsy) have been available for many decades. A more recent treatment for neurological disorders involves electrical stimulation of a target tissue to reduce symptoms or effects of the disorder. Such therapeutic electrical signals have been successfully applied to brain, spinal cord, and cranial nerves tissues improve or ameliorate a variety of conditions. A particular example of such a therapy involves applying an electrical signal to the vagus nerve to reduce or eliminate epileptic seizures, as described in U.S. Pat. Nos. 4,702,254, 4,867,164, and 5,025,807, which are hereby incorporated herein by reference in their entirety.

The endogenous electrical activity (i.e., activity attributable to the natural functioning of the patient's own body) of a neural structure may be modulated in a variety of ways. One such way is by applying exogenous (i.e., from a source other than the patient's own body) electrical, chemical, or mechanical signals to the neural structure. In some embodiments, the exogenous signal (“neurostimulation” or “neuromodulation”) may involve the induction of afferent action potentials, efferent action potentials, or both, in the neural structure. In some embodiments, the exogenous (therapeutic) signal may block or interrupt the transmission of endogenous (natural) electrical activity in the target neural structure. Electrical signal therapy may be provided by implanting an electrical device underneath the skin of a patient and delivering an electrical signal to a nerve such as a cranial nerve.

In one embodiment, the electrical signal therapy may involve detecting a symptom or event associated with the patient's medical condition, and the electrical signal may be delivered in response to the detection. This type of stimulation is generally referred to as “closed-loop,” “active,” “feedback,” “contingent” or “triggered” stimulation. Alternatively, the system may operate according to a predetermined program to periodically apply a series of electrical pulses to the nerve intermittently throughout the day, or over another predetermined time interval. This type of stimulation is generally referred to as “open-loop,” “passive,” “non-feedback,” “non-contingent” or “prophylactic,” stimulation.

In other embodiments, both open- and closed-loop stimulation modes may be used. For example, an open-loop electrical signal may operate as a “default” program that is repeated according to a programmed on-time and off-time until a condition is detected by one or more body sensors and/or algorithms. The open-loop electrical signal may then be interrupted in response to the detection, and the closed-loop electrical signal may be applied—either for a predetermined time or until the detected condition has been effectively treated. The closed-loop signal may then be interrupted, and the open-loop program may be resumed. Therapeutic electrical stimulation may be applied by an implantable medical device (IMD) within the patient's body or, in some embodiments, externally.

Closed-loop stimulation of the vagus nerve has been proposed to treat epileptic seizures. Many patients with intractable, refractory seizures experience changes in heart rate and/or other autonomic body signals near the clinical onset of seizures. In some instances the changes may occur prior to the clinical onset, and in other cases the changes may occur at or after the clinical onset. Where the changes involves heart rate, most often the rate increases, although in some instances a drop or a biphasic change (up-then-down or down-then-up) may occur. It is possible using a heart rate sensor to detect such changes and to initiate therapeutic electrical stimulation (e.g., VNS) based on the detected change. The closed-loop therapy may be a modified version of an open-loop therapy. See, e.g., U.S. Pat. Nos. 5,928,272, and 6,341,236, each hereby incorporated by reference herein. The detected change may also be used to warn a patient or third party of an impending or occurring seizure.

VNS therapy for epilepsy patients typically involves a train of electrical pulses applied to the nerve with an electrode pair including a cathode and an anode located on a left or right main vagal trunk in the neck (cervical) area. Only the cathode is capable of generating action potentials in nerve fibers within the vagus nerve; the anode may block some or all of the action potentials that reach it (whether endogenous or exogenously generated by the cathode). VNS as an epilepsy therapy involves modulation of one or more brain structures. Therefore, to prevent the anode from blocking action potentials generated by the cathode from reaching the brain, the cathode is usually located proximal to the brain relative to the anode. For vagal stimulation in the neck area, the cathode is thus usually the upper electrode and the anode is the lower electrode. This arrangement is believed to result in partial blockage of action potentials distal to or below the anode (i.e., those that would travel through the vagus nerve branches innervating the lungs, heart and other viscerae). Using an upper-cathode/lower-anode arrangement has also been favored to minimize any effect of the vagus nerve stimulation on the heart.

Stimulation of the left vagus nerve, for treatment of epilepsy has complex effects on heart rate (see Frei & Osorio, Epilepsia 2001), one of which includes slowing of the heart rate, while stimulation of the right vagus nerve has a more prominent bradycardic effect. Electrical stimulation of the right vagus nerve has been proposed for use in the operating room to slow the heart during heart bypass surgery, to provide a surgeon with a longer time period to place sutures between heartbeats (see, e.g., U.S. Pat. No. 5,651,373). Some patents discussing VNS therapy for epilepsy treatment express concern with the risk of inadvertently slowing the heart during stimulation. In U.S. Pat. No. 4,702,254, it is suggested that by locating the VNS stimulation electrodes below the inferior cardiac nerve, “minimal slowing of the heart rate is achieved” (col. 7 lines 3-5), and in U.S. Pat. No. 6,920,357, the use of a pacemaker to avoid inadvertent slowing of the heart is disclosed.

Cranial nerve stimulation has also been suggested for disorders outside the brain such as those affecting the gastrointestinal system, the pancreas (e.g., diabetes, which often features impaired production of insulin by the islets of Langerhans in the pancreas), or the kidneys. Electrical signal stimulation of either the brain alone or the organ alone may have some efficacy in treating such medical conditions, but may lack maximal efficacy.

While electrical stimulation has been used for many years to treat a number of conditions, a need exists for improved VNS methods of treating epilepsy and its cardiac co-morbidities as well as other brain and non-brain disorders.

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to a method of treating a patient having epilepsy comprising coupling a first electrode and a second electrode to a vagus nerve of the patient, wherein the first electrode is coupled to a main trunk of a vagus nerve and the second electrode is coupled to a cardiac branch of a vagus nerve, providing an electrical signal generator coupled to the first electrode and the second electrode, receiving at least one body data stream, analyzing the at least one body data stream using a seizure or event detection algorithm to determine whether or not the patient has had an epileptic seizure, applying a first electrical signal from the electrical signal generator to the main trunk of a vagus nerve using the first electrode as a cathode, based on a determination that the patient has not had an epileptic seizure, and applying a second electrical signal from the electrical signal generator to the cardiac branch of the vagus nerve using the second electrode as a cathode, based on a determination that the patient has had an epileptic seizure.

In one aspect, the present invention relates to a method of treating a patient having epilepsy comprising sensing a cardiac signal and a kinetic signal of the patient, analyzing at least one of the cardiac signal and the kinetic signal; determining whether or not the patient has had an epileptic seizure based on the analyzing, in response to a determination that the patient has had an epileptic seizure, determining whether or not the seizure is characterized by an increase in the patient's heart rate, applying a first electrical signal to a main trunk of a vagus nerve of the patient using a first electrode as a cathode based on one of a) a determination that the patient has not had an epileptic seizure, and b) a determination that the patient has had an epileptic seizure that is not characterized by an increase in the patient's heart rate, wherein the first electrode is coupled to the main trunk, and applying a second electrical signal to a cardiac branch of a vagus nerve of the patient using a second electrode as a cathode based on a determination that the patient has had an epileptic seizure characterized by an increase in the patient's heart rate, wherein the second electrode is coupled to the cardiac branch.

In one aspect, the present invention relates to a system for treating a medical condition in a patient, comprising a first electrode and a second electrode coupled to a vagus nerve of the patient, wherein the first electrode is proximal to the brain relative to the second electrode, and the second electrode is coupled to a cardiac branch of the vagus nerve, a programmable electrical signal generator, a sensor for sensing at least one body data stream, a seizure detection module capable of analyzing the at least one body data stream and determining, based on the analyzing, whether or not the patient has had an epileptic seizure, and a logic unit for applying a first electrical signal to the vagus nerve using the first electrode as a cathode based upon a determination by the seizure detection module that the patient has not had an epileptic seizure, and for applying a second electrical signal to the vagus nerve using the second electrode as a cathode based upon a determination by the seizure detection module that the patient has had an epileptic seizure.

In one aspect, the present invention relates to a method of treating a patient having epilepsy comprising applying a first electrical signal to a main trunk of a vagus nerve of the patient, wherein the first electrical signal is an open-loop electrical signal having a programmed on-time and a programmed off-time, sensing at least one body signal of the patient, determining the start of an epileptic seizure based on the at least one body signal, determining whether or not the seizure is characterized by an increase in the patient's heart rate, applying a second, closed-loop electrical signal to the main trunk of the vagus nerve based on a determination that the epileptic seizure is not characterized by an increase in the patient heart rate, and applying a third, closed-loop electrical signal to a cardiac branch of a vagus nerve based on a determination that the seizure is characterized by an increase in the patient's heart rate, wherein the third electrical signal is applied to reduce the patient's heart rate.

In one aspect, the present invention relates to a method of treating a patient having epilepsy comprising sensing at least one body signal of the patient, determining whether or not the patient has had an epileptic seizure based on the at least one body signal, sensing a cardiac signal of the patient, in response to a determination that the patient has had an epileptic seizure, determining whether or not the seizure is characterized by an increase in the patient's heart rate, applying a first electrical signal to a left vagus nerve of the patient using a first electrode as a cathode based on one of a) a determination that the patient has not had an epileptic seizure, and b) a determination that the patient has had an epileptic seizure that is not characterized by an increase in the patient's heart rate, wherein the first electrode is coupled to the left vagus nerve, and applying a second electrical signal to a right vagus nerve of the patient using a second electrode as a cathode based on a determination that the patient has had an epileptic seizure characterized by an increase in the patient's heart rate, wherein the second electrode is coupled to the right vagus nerve.

In one aspect, the present invention relates to a method of treating a patient having epilepsy comprising sensing at least one body signal of the patient, determining whether or not the patient has had an epileptic seizure based on the at least one body signal, sensing a cardiac signal of the patient, in response to a determination that the patient has had an epileptic seizure, determining whether or not the seizure is associated with a change in the patient's cardiac signal, applying a first electrical signal to a left vagus nerve of the patient using a first electrode as a cathode based on one of a) a determination that the patient has not had an epileptic seizure, and b) a determination that the patient has had an epileptic seizure that is not associated with a change in the patient's cardiac signal, wherein the first electrode is coupled to the left vagus nerve, and applying a second electrical signal to a right vagus nerve of the patient using a second electrode as a cathode based on a determination that the patient has had an epileptic seizure associated with a change in the patient's cardiac signal, wherein the second electrode is coupled to the right vagus nerve.

In one aspect, the present invention relates to a method of treating a patient having epilepsy comprising sensing a cardiac signal and a kinetic signal of the patient, analyzing at least one of the cardiac signal and the kinetic signal; determining whether or not the patient has had an epileptic seizure based on the analyzing, in response to a determination that the patient has had an epileptic seizure, determining whether or not the seizure is characterized by cardiac changes, applying a first electrical signal to a left main trunk of a vagus nerve of the patient using a first electrode as a cathode based on one of a) a determination that the patient has not had an epileptic seizure, and b) a determination that the patient has had an epileptic seizure that is not characterized by cardiac changes, wherein the first electrode is coupled to the left main trunk, and applying a second electrical signal to a cardiac branch of a vagus nerve of the patient using a second electrode as a cathode based on a determination that the patient has had an epileptic seizure characterized by cardiac changes, wherein the second electrode is coupled to the cardiac branch.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:

FIGS. 1A-1C provide stylized diagrams of an implantable medical device implanted into a patient's body for providing first and second electrical signals to a vagus nerve of a patient for treating epileptic seizures, in accordance with one illustrative embodiment of the present invention;

FIG. 2 illustrates a block diagram depiction of an implantable medical device of FIG. 1, in accordance with one illustrative embodiment of the present invention;

FIG. 3 illustrates a block diagram depiction of an electrode polarity reversal unit shown in FIG. 2, in accordance with one illustrative embodiment of the present invention;

FIG. 4 illustrates a flowchart depiction of a method for providing first and second electrical signals to a main trunk and a cardiac branch of a vagus nerve, respectively, based upon whether or not the patient has had an epileptic seizure, in accordance with an illustrative embodiment of the present invention;

FIG. 5 illustrates a flowchart depiction of a method for providing first and second electrical signals to a main trunk and a cardiac branch of a vagus nerve, respectively, based upon whether or not at least one of a cardiac signal and a kinetic signal indicates that the patient has had an epileptic seizure, and whether the seizure is characterized by an increase in heart rate, in accordance with an illustrative embodiment of the present invention;

FIG. 6 illustrates a flowchart depiction of a method for providing a first, open-loop electrical signal to a main trunk of a vagus nerve, a second, closed-loop electrical signal to the main trunk of the vagus nerve based upon the patient having had an epileptic seizure not characterized by an increase in heart rate, and a third, closed-loop electrical signal to a cardiac branch of a vagus nerve based upon the patient having had an epileptic seizure characterized by an increase in heart rate, in accordance with an illustrative embodiment of the present invention; and

FIG. 7 is a flowchart depiction of a method for providing closed-loop vagus nerve stimulation for a patient with epilepsy by stimulating a right vagus nerve in response to detecting a seizure with tachycardia and stimulating a left vagus nerve in the absence of such a detection.

While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

Illustrative embodiments of the invention are described herein. For clarity, not all features of an actual implementation are provided in detail. In any actual embodiment, numerous implementation-specific decisions must be made to achieve the design-specific goals. Such a development effort, while possibly complex and time-consuming, would nevertheless be a routine task for persons of skill in the art given this disclosure.

This application does not intend to distinguish between components that differ in name but not function. “Including” and “includes” are used in an open-ended fashion, and should be interpreted to mean “including, but not limited to.” “Couple” or “couples” is intended to mean either a direct or an indirect electrical connection. “Direct contact,” “direct attachment,” or providing a “direct coupling” indicates that a surface of a first element contacts the surface of a second element with no substantial attenuating medium there between. Small quantities of substances, such as bodily fluids, that do not substantially attenuate electrical connections do not vitiate direct contact. “Or” is used in the inclusive sense (i.e., “and/or”) unless a specific use to the contrary is explicitly stated.

“Electrode” or “electrodes” may refer to one or more stimulation electrodes (i.e., electrodes for applying an electrical signal generated by an IMD to a tissue), sensing electrodes (i.e., electrodes for sensing a body signal), and/or electrodes capable of either stimulation or sensing. “Cathode” and “anode” have their standard meanings, as the electrode at which current leaves the IMD system and the electrode at which current enters the IMD system, respectively. Reversing the polarity of the electrodes can be effected by any switching technique known in the art.

A “pulse” is used herein to refer to a single application of electrical charge from the cathode to target neural tissue. A pulse may include both a therapeutic portion (in which most or all of the therapeutic or action-potential-generating effect occurs) and a charge-balancing portion in which the polarity of the electrodes are reversed and the electrical current is allowed to flow in the opposite direction to avoid electrode and/or tissue damage. Individual pulses are separated by a time period in which no charge is delivered to the nerve, which can be called the “interpulse interval.” A “burst” is used herein to refer to a plurality of pulses, which may be separated from other bursts by an interburst interval in which no charge is delivered to the nerve. The interburst intervals have a duration exceeding the interpulse interval duration. In one embodiment, the interburst interval is at least twice as long as the interpulse interval. The time period between the end of the last pulse of a first burst and the initiation of the first pulse of the next subsequent burst can be called the “interburst interval.” In one embodiment, the interburst interval is at least 100 msec.

A plurality of pulses can refer to any of (a) a number of consecutive pulses within a burst, (b) all the pulses of a burst, or (c) a number of consecutive pulses including the final pulse of a first burst and the first pulse of the next subsequent burst.

“Stimulate,” “stimulating” and “stimulator” may generally refer to applying a signal, stimulus, or impulse to neural tissue (e.g., a volume of neural tissue in the brain or a nerve) for affecting it neuronal activity. While the effect of such stimulation on neuronal activity is termed “modulation,” for simplicity, the terms “stimulating” and “modulating”, and variants thereof, are sometimes used interchangeably herein. The modulation effect of a stimulation signal on neural tissue may be excitatory or inhibitory, and may potentiate acute and/or long-term changes in neuronal activity. For example, the modulation effect of a stimulation signal may comprise: (a) initiating action potentials in the target neural tissue; (b) inhibition of conduction of action potentials (whether endogenous or exogenously generated, or blocking their conduction (e.g., by hyperpolarizing or collision blocking), (c) changes in neurotransmitter/neuromodulator release or uptake, and (d) changes in neuro-plasticity or neurogenesis of brain tissue. Applying an electrical signal to an autonomic nerve may comprise generating a response that includes an afferent action potential, an efferent action potential, an afferent hyperpolarization, an efferent hyperpolarization, an afferent sub-threshold depolarization, and/or an efferent sub-threshold depolarization.

A variety of stimulation therapies may be provided in embodiments of the present invention. Different nerve fiber types (e.g., A, B, and C-fibers that may be targeted) respond differently to stimulation from electrical signals because they have different conduction velocities and stimulation threshold. Certain pulses of an electrical stimulation signal, for example, may be below the stimulation threshold for a particular fiber and, therefore, may generate no action potential. Thus, smaller or narrower pulses may be used to avoid stimulation of certain nerve fibers (such as C-fibers) and target other nerve fibers (such as A and/or B fibers, which generally have lower stimulation thresholds and higher conduction velocities than C-fibers). Additionally, techniques such as a pre-pulse may be employed wherein axons of the target neural structure may be partially depolarized (e.g., with a pre-pulse or initial phase of a pulse) before a greater current is delivered to the target (e.g., with a second pulse or an initial phase such a stairstep pre-pulse to deliver a larger quantum of charge). Furthermore, opposing polarity phases separated by a zero current phase may be used to excite particular axons or postpone nerve fatigue during long term stimulation.

Cranial nerve stimulation, such as vagus nerve stimulation (VNS), has been proposed to treat a number of medical conditions, including epilepsy and other movement disorders, depression and other neuropsychiatric disorders, dementia, traumatic brain injury, coma, migraine headache, obesity, eating disorders, sleep disorders, cardiac disorders (such as congestive heart failure and atrial fibrillation), hypertension, endocrine disorders (such as diabetes and hypoglycemia), and pain, among others. See, e.g., U.S. Pat. Nos. 4,867,164; 5,299,569; 5,269,303; 5,571,150; 5,215,086; 5,188,104; 5,263,480; 6,587,719; 6,609,025; 5,335,657; 6,622,041; 5,916,239; 5,707,400; 5,231,988; and 5,330,515. Despite the variety of disorders for which cranial nerve stimulation has been proposed or suggested, the fact that detailed neural pathways for many (if not all) cranial nerves remain relatively unknown, makes predictions of efficacy for any given disorder difficult or impossible. Even if such pathways were known, the precise stimulation parameters that would modulate particular pathways relevant to a particular disorder generally cannot be predicted.

It appears that sympatho-vagal imbalance (lower vagal and higher sympathetic tone) plays an important role in generation of a wide spectrum of ictal and inter-ictal alterations in cardiac dynamics, ranging from rare uni-focal PVCs to cardiac death. Without being bound by theory, restoration of the vagal tone to a level sufficient to counteract the pathological effects of elevated catecholamines may serve a cardio-protective purpose that would be particularly beneficial in patients with pharmaco-resistant epilepsies, who are at highest risk for SUDEP.

In one embodiment, the present invention provides methods and apparatus to increase cardiac vagal tone in epilepsy patients by timely delivering therapeutic electrical currents to the trunks of the right or left vagus nerves or to their cardiac rami (branches), in response to increases in sympathetic tone, by monitoring among others, heart rate, heart rhythm, EKG morphology, blood pressure, skin resistance, catecholamine or their metabolites and neurological signals such as EEG/ECoG, kinetic (e.g., amplitude velocity, direction of movements) and cognitive (e.g., complex reaction time).

In one embodiment, the present invention provides a method of treating a medical condition selected from the group consisting of epilepsy, neuropsychiatric disorders (including but not limited to depression), eating disorders/obesity, traumatic brain injury, addiction disorders, dementia, sleep disorders, pain, migraine, endocrine/pancreatic disorders (including but not limited to diabetes), motility disorders, hypertension, congestive heart failure/cardiac capillary growth, hearing disorders, angina, syncope, vocal cord disorders, thyroid disorders, pulmonary disorders, gastrointestinal disorders, kidney disorders, and reproductive endocrine disorders (including infertility).

FIGS. 1A-1C depict a stylized implantable medical system 100 for implementing one or more embodiments of the present invention. FIGS. 1A-1C illustrate an electrical signal generator 110 having main body 112 comprising a case or shell 121 (FIG. 1B) with a header 116 (FIG. 1A, 1B) for connecting to a lead assembly 122. An electrode assembly 125 is provided at a distal end of lead assembly 122, and includes one or more electrodes 125-1, 125-2, 125-3 that may be coupled to a neural target tissue such as a vagus nerve 127, which may include an upper main trunk portion 127-1 above a cardiac branch and a lower main trunk portion 127-3 below a cardiac branch.

Electrode assembly 125, preferably comprising at least an electrode pair, is conductively connected to the distal end of an insulated, electrically conductive lead assembly 122, which preferably comprises a pair of lead wires (one wire for each electrode of an electrode pair). Lead assembly 122 is attached at its proximal end to one or more connectors on header 116 (FIG. 1B) on case 121. Electrode assembly 125 may be surgically coupled to a cranial nerve, such as vagus nerve 127 in the patient's neck or another location, e.g., near the diaphragm. In alternative embodiments, the therapeutic electrical signal may also be applied to other cranial nerves, such as the trigeminal nerve.

In one embodiment, at least one electrode 125-1 may be coupled to an upper main trunk 127-1 of the vagus nerve, and at least one electrode 125-2 may be coupled to a cardiac branch 127-2 of the vagus nerve. Main trunk electrode 125-1 may be used to provide a first electrical signal to the main trunk 127-1, and cardiac branch electrode 125-2 may be used to provide a second electrical signal to cardiac branch 127-2. The first electrical signal may generate afferent action potentials to modulate electrical activity of the patient's brain without significantly affecting the patient's heart rate. The second electrical signal may generate efferent action potentials to module the cardiac activity of the patient, and in particular may slow the patient's heart rate and maintain or restore a sympathetic/parasympathetic balance to physiological levels. In an alternative embodiment, an electrode 125-3 may be coupled to a lower main trunk 127-3 of the vagus nerve, either in addition to or instead of the upper main trunk electrode 125-1. Suitable electrode assemblies are available from Cyberonics, Inc., Houston, Tex., USA as the Model 302, PerenniaFlex and PerenniaDura electrode assemblies. Persons of skill in the art will appreciate, however, that many electrode designs could be used in embodiments of the present invention, including unipolar electrodes.

In some embodiments, a heart rate sensor 130, and/or a kinetic sensor 140 (e.g., a triaxial accelerometer) may be included in the system 100 to sense one or more of a cardiac signal or data stream and a kinetic data stream of the patient. In one embodiment, the heart rate sensor may comprise a separate element 130 that may be coupled to generator 110 through header 116 as illustrated in FIG. 1A. In another embodiment, the electrodes 125-1, 125-2, 125-3 and/or the case 121 may be used as sensing electrodes to sense heart rate. An accelerometer may be provided inside generator 110 in one embodiment to sense a kinetic signal (e.g., body movement) of the patient. One or more of the heart rate sensor 130 and the kinetic sensor 140 may be used by a seizure detection algorithm in the system 100 to detect epileptic seizures. In alternative embodiments, other body signals (e.g., blood pressure, brain activity, blood oxygen/CO2 concentrations, temperature, skin resistivity, etc.) of the patient may be sensed and used by the seizure detection algorithm to detect epileptic seizures. Signal generator 110 may be implanted in the patient's chest in a pocket or cavity formed by the implanting surgeon below the skin (indicated by line 145, FIG. 1A).

Returning to FIGS. 1A and 1C, a first electrode 125-1 may be wrapped or otherwise electrically coupled to an upper main trunk 127-1 of a vagus nerve 127 of the patient, and a second electrode 125-2 may be wrapped or coupled to a cardiac branch 127-2 of the vagus nerve. In one embodiment, a third electrode 125-3 may be coupled to a lower main trunk 127-3 of the vagus nerve below the cardiac branch 127-2 of the vagus nerve, instead of or in addition to first electrode 125-1 coupled to the upper main trunk above the cardiac branch. In some embodiments, third electrode 125-3 may be omitted. Electrode assembly 125 may be secured to the nerve by a spiral anchoring tether 128 (FIG. 1C), which does not include an electrode. Lead assembly 122 may further be secured, while retaining the ability to flex, by a suture connection 130 to nearby tissue (FIG. 1C).

In one embodiment, the open helical design of the electrodes 125-1, 125-2, 125-3 is self-sizing, flexible, minimize mechanical trauma to the nerve and allow body fluid interchange with the nerve. The electrode assembly 125 preferably conforms to the shape of the nerve, providing a low stimulation threshold by allowing a large stimulation contact area with the nerve. Structurally, the electrode assembly 125 comprises an electrode ribbon (not shown) for each of electrodes 125-1, 125-2, 125-3, made of a conductive material such as platinum, iridium, platinum-iridium alloys, and/or oxides thereof. The electrode ribbons are individually bonded to an inside surface of an elastomeric body portion of the spiral electrodes 125-1, 125-2, 125-3 (FIG. 1C), which may comprise spiral loops of a multi-loop helical assembly. Lead assembly 122 may comprise three distinct lead wires or a triaxial cable that are respectively coupled to one of the conductive electrode ribbons. One suitable method of coupling the lead wires to the electrodes 125-1, 125-2, 125-3 comprises a spacer assembly such as that disclosed in U.S. Pat. No. 5,531,778, although other known coupling methods may be used.

The elastomeric body portion of each loop may be composed of silicone rubber or other biocompatible elastomeric compounds, and the fourth loop 128 (which may have no electrode in some embodiments) acts as the anchoring tether for the electrode assembly 125.

In one embodiment, electrical pulse generator 110 may be programmed with an external computer 150 using programming software known in the art for stimulating neural structures, and a programming wand 155 to facilitate radio frequency (RF) communication between the external computer 150 (FIG. 1A) and the implanted pulse generator 110. In one embodiment, wand 155 and software permit wireless, non-invasive communication with the generator 110 after implant. Wand 155 may be powered by internal batteries, and provided with a “power on” light to indicate sufficient power for communications. Another indicator light may be provided to show that data transmission is occurring between the wand and the generator. In other embodiments, wand 155 may be omitted, e.g., where communications occur in the 401-406 MHz bandwidth for Medical Implant Communication Service (MICS band).

In some embodiments of the invention, a body data stream may be analyzed to determine whether or not a seizure has occurred. Many different body data streams and seizure detection indices have been proposed for detecting epileptic seizures. Additional details on method of detecting seizure from body data are provided in co-pending U.S. patent application Ser. No. 12/896,525, filed Oct. 1, 2010, 13/098,262, filed Apr. 29, 2011, and 13/288,886, filed Nov. 3, 2011, each hereby incorporated by reference in its entirety herein. Seizure detection based on the patient's heart rate (as sensed by implanted or external electrodes), movement (as sensed by, e.g., a triaxial accelerometer), responsiveness, breathing, blood oxygen saturation, skin resistivity/conductivity, temperature, brain activity, and a number of other body data streams are provided in the foregoing co-pending applications.

In one embodiment, the present invention provides a method for treating a patient with epilepsy in which a body data stream is analyzed using a seizure detection algorithm to determine whether or not the patient has had an epileptic seizure. If the analysis results in a determination that the patient has not had an epileptic seizure, a signal generator may apply a first electrical signal to a main trunk of a vagus nerve of the patient. If the analysis results in a determination that the patient has had an epileptic seizure, the signal generator may apply a second electrical signal to a cardiac branch of a vagus nerve of the patient. In some embodiments, the application of the first electrical signal to the main trunk is terminated, and only the second electrical signal to the cardiac branch is provided once a seizure is detected.

In alternative embodiments, both the first and second electrical signals may be applied to the main trunk and cardiac branch, respectively, of the vagus nerve in response to a determination that the patient has had a seizure (i.e., the first electrical signal continues to be applied to the main trunk of the vagus nerve and the second signal is initiated). Where both the first and second electrical signals are provided, the two signals may be provided sequentially, or in alternating fashion to the main trunk and the cardiac branch by controlling the polarity of the electrodes on the main trunk and cardiac branch. In one embodiment, the first signal may be provided to the main trunk by using one of the upper main trunk electrode 125-1 or the lower main trunk electrode 125-3 as the cathode and the cardiac branch electrode 125-2 as the anode, or by using both of the upper main trunk electrode and the lower main trunk electrode as the cathode and the anode. The second signal may be provided (e.g., by rapidly changing the polarity of the electrodes) by using the cardiac branch electrode 125-2 as the cathode and a main trunk electrode 125-1 or 125-3 as the anode.

In still other embodiments, the second electrical signal is applied to the cardiac branch of the vagus nerve only of the analysis results in a determination that the patient has had an epileptic event that is accompanied by an increase in heart rate, and the second electrical signal is used to lower the heart rate back towards a rate that existed prior to the seizure onset. Without being bound by theory, the present inventors believe that slowing the heart rate at the onset of seizures—particularly where the seizure is accompanied by an increase in heart rate—may improve the ability of VNS therapy to provide cardio-protective benefits.

Prior patents describing vagus nerve stimulation as a medical therapy have cautioned that undesired slowing of the heart rate may occur, and have proposed various methods of avoiding such a slowing of the heart rate. In U.S. Pat. No. 6,341,236, it is suggested to sense heart rate during delivery of VNS and if a slowing of the heart rate is detected, either suspending delivery of the VNS signal or pacing the heart using a pacemaker. The present application discloses a VNS system that detects epileptic seizures, particularly epileptic seizures accompanied by an increase in heart rate, and intentionally applies an electrical signal to slow the heart rate in response to such a detection. In another aspect, the present application discloses VNS systems that provide a first electrical signal to modulate only the brain during periods in which no seizure has been detected, and either 1) a second electrical signal to modulate only the heart (to slow its rate) or 2) both a first electrical signal to the brain and a second electrical signal to the heart, in response to a detection of the onset of an epileptic seizure. These electrical signals may be delivered simultaneously, sequentially (e.g., delivery of stimulation to the brain precedes delivery of stimulation to the heart or vice versa), or delivery may be interspersed/interleaved.

The first electrode may be used as a cathode to provide an afferent first electrical signal to modulate the brain of the patient via main trunk electrode 125-1. Either second electrode 125-2 or a third electrode 125-3 may be used as an anode to complete the circuit. The second electrode may be used as a cathode to provide an efferent second electrical signal to slow the heart rate of the patient via cardiac branch electrode 125-2. Either first electrode 125-1 or a third electrode 125-3 may be used as an anode to complete the circuit. In one embodiment, the first electrical signal may be applied to the upper (127-1) or lower (127-3) main trunk of the vagus nerve in an open-loop manner according to programmed parameters including an off-time and an on-time. The on-time and off-time together establish the duty cycle determining the fraction of time that the signal generator applies the first electrical. In one embodiment, the off-time may range from 7 seconds to several hours or even longer, and the on-time may range from 5 seconds to 300 seconds. It should be noted that the duty cycle does not indicate when current is flowing through the circuit, which is determined from the on-time together with the pulse frequency (usually 10-200, Hz, and more commonly 20-30 Hz) and pulse width (typically 0.1-0.5 milliseconds). The first electrical signal may also be defined by a current magnitude (e.g., 0.25-3.5 milliamps), and possibly other parameters (e.g., pulse width, and whether or not a current ramp-up and/or ramp-down is provided, a frequency, and a pulse width.

In one embodiment, a seizure detection may result in both applying the first electrical signal to provide stimulation to the brain in close proximity to a seizure detection (which may interrupt or terminate the seizure), as well as application of the second electrical signal which may slow the heart, thus exerting a cardio-protective effect. In a particular embodiment, the second electrical signal is applied only in response to a seizure detection that is characterized by (or accompanied or associated with) an increase in heart rate, and is not applied in response to seizure detections that are not characterized by an increase in heart rate. In this manner, the second electrical signal may help interrupt the seizure by restoring the heart to a pre-seizure baseline heart rate when the patient experiences ictal tachycardia (elevated heart rate during the seizure), while leaving the heart rate unchanged if the seizure has no significant effect on heart rate.

In still further embodiments, additional logical conditions may be established to control when the second electrical signal is applied to lower the patient's heart rate following a seizure detection. In one embodiment, the second electrical signal is applied only if the magnitude of the ictal tachycardia rises above a defined level. In one embodiment, the second electrical signal is applied to the cardiac branch only if the heart rate increases by a threshold amount above the pre-ictal baseline heart rate (e.g., more than 20 beats per minute above the baseline rate). In another embodiment, the second electrical signal is applied to the cardiac branch only if the heart rate exceeds an absolute heart rate threshold (e.g., 100 beats per minute, 120 beats per minute, or other programmable threshold). In a further embodiment, a duration constraint may be added to one or both of the heart rate increase or absolute heart rate thresholds, such as a requirement that the heart rate exceed the baseline rate by 20 beats per minute for more than 10 seconds, or exceed 110 beats per minute for more than 10 seconds, before the second electrical signal is applied to the cardiac branch in response to a seizure detection.

In another embodiment, the heart rate sensor continues to monitor the patient's heart rate during and/or after application of the second electrical signal, and the second electrical signal is interrupted or terminated if the patient's heart rate is reduced below a low heart rate threshold, which may be the baseline heart rate that the patient experienced prior to the seizure, or a rate lower or higher than the baseline pre-ictal heart rate. The low rate threshold may provide a measure of safety to avoid undesired events such as bradycardia and/or syncope.

In yet another embodiment, heart rate sensor 130 may continue to monitor heart rate and/or kinetic sensor 140 may continue to monitor body movement in response to applying the second electrical signal, and the second electrical signal may be modified (e.g., by changing one or more parameters such as pulse frequency, or by interrupting and re-initiating the application of the second electrical signal to the cardiac branch of the vagus nerve) to control the heart rate below an upper heart rate threshold and/or body movement exceeds one or more movement thresholds. For example, the frequency or duration of the second electrical signal applied to the cardiac branch of the vagus nerve may be continuously modified based the instantaneous heart rate as monitored during the course of a seizure to control what would otherwise be an episode of ictal tachycardia below an upper heart rate threshold. In one exemplary embodiment, the second electrical signal may be programmed to provide a 30-second pulse burst at 30 Hz, with the pulses having a pulse width of 0.25 milliseconds and a current of 1.5 milliamps. If, at the end of the 30 second burst, the heart rate remains above 120 beats per minute, and is continuing to rise, the burst may be extended to 1 minute instead of 30 seconds, the frequency may be increased to 50 Hz, the pulse width may be increased to 350 milliseconds, or combinations of the foregoing. In still further embodiments, additional therapies (e.g., oxygen delivery, drug delivery, cooling therapies, etc.) may be provided to the patient if the body data (heart rate, kinetic activity, etc.) indicates that the patient's seizure is not under control or terminated.

Abnormalities in EKG morphology or rhythm may also trigger delivery of current to the heart via the trunks of vagi or its cardiac rami. In other embodiments, pharmacological agents such as beta-blockers may be automatically released into a patient's blood stream in response to the detection of abnormal heart activity during or between seizures.

In one embodiment, the first electrical signal and the second electrical signal are substantially identical. In another embodiment, the first electrical signal may vary from the second electrical signal in terms of one or more of pulse width, number of pulses, amplitude, frequency, stimulation on-time, and stimulation off-time, among other parameters.

The number of pulses applied to the main trunk or cardiac branch, respectively, before changing the polarity of the first and second electrodes need not be one. Thus, two or more pulses may be applied to the main trunk before applying pulses to the cardiac branch of the vagus nerve. More generally, the first and second signals can be independent of one another and applied according to timing and programming parameters controlled by the controller 210 and stimulation unit 220.

In one embodiment, one or more pulse bursts of the first electrical signal are applied to the main trunk of the vagus nerve in response to a detected seizure before applying one or more bursts of the second electrical signal to the cardiac branch. In another embodiment, the first and second signals are interleaved on a pulse-by-pulse basis under the control of the controller 210 and stimulation unit 220.

Typically, VNS can be performed with pulse frequency of 20-30 Hz (resulting in a number of pulses per burst of 140-1800, at a burst duration from 7-60 sec). In one embodiment, at least one of the first electrical signal and the second electrical signal comprises a microburst signal. Microburst neurostimulation is discussed by U.S. Ser. No. 11/693,451, filed Mar. 2, 2007 and published as United States patent Publication No. 20070233193, and incorporated herein by reference in its entirety. In one embodiment, at least one of the first electrical signal, the second electrical signal, and the third electrical signal is characterized by having a number of pulses per microburst from 2 pulses to about 25 pulses, an interpulse interval of about 2 msec to about 50 msec, an interburst period of at least 100 msec, and a microburst duration of less than about 1 sec.

Cranial nerves such as the vagus nerve include different types of nerve fibers, such as A-fibers, B-fibers and C-fibers. The different fiber types propagate action potentials at different velocities. Each nerve fiber can propagate action potentials in only one direction (e.g., afferently to the brain or efferently to the heart and/or viscera). Moreover, only the cathode can generate action potentials (by depolarizing axons). It is believed that the anode may block at least some action potentials traveling to it from the cathode. For example, referring to FIG. 1, both afferent and efferent action potentials may be generated in an upper main trunk of vagus nerve 127-1 by applying a pulse to the nerve using upper main trunk electrode 125-1 as a cathode and cardiac branch electrode 125-2 as an anode. Efferent action potentials generated at upper main trunk electrode 125-1 and traveling toward the heart on cardiac branch 127-2 may be blocked by cardiac branch anode 125-2. Efferent action potentials traveling from the upper main trunk 127-1 to the lower organs in lower main trunk 127-3 may be either blocked (by using lower main trunk electrode 125-3 as an anode either with or instead of cardiac branch electrode 125-2) or allowed to travel to the lower organs (by not using electrode structure 125-3 as an electrode).

Efferent action potentials may be generated and allowed to travel to the heart by reversing the polarity of the electrodes and applying a second electrical signal to the upper main trunk electrode 125-1 and cardiac branch electrode 125-2. If cardiac branch electrode 125-2 is used as a cathode, action potentials traveling efferently to the heart in cardiac branch 127-2 will not be blocked in the embodiment of FIG. 1, while at least some afferent action potentials generated traveling toward the brain may be blocked by upper electrode 125-2, which functions as the anode for the second electrical signal.

In a further embodiment of the invention, rapid changes in electrode polarity may be used to generate action potentials to collision block action potentials propagating in the opposite direction. To generalize, in some embodiments, the vagus nerve can be selectively stimulated to propagate action potentials either afferently (i.e., to the brain) or efferently (i.e., to the heart and/or lower organs/viscerae).

Turning now to FIG. 2, a block diagram depiction of an implantable medical device, in accordance with one illustrative embodiment of the present invention is illustrated. The IMD 200 may be coupled to various electrodes 125 via lead(s) 122 (FIGS. 1A, 1C). First and second electrical signals used for therapy may be transmitted from the IMD 200 to target areas of the patient's body, specifically to various electrodes associated with the leads 122. Stimulation signals from the IMD 200 may be transmitted via the leads 122 to stimulation electrodes (electrodes that apply the therapeutic electrical signal to the target tissue) associated with the electrode assembly 125, e.g., 125-1, 125-2, 125-3 (FIG. 1A).

The IMD 200 may comprise a controller 210 capable of controlling various aspects of the operation of the IMD 200. The controller 210 is capable of receiving internal data and/or external data and controlling the generation and delivery of a stimulation signal to target tissues of the patient's body. For example, the controller 210 may receive manual instructions from an operator externally, may perform stimulation based on internal calculations and programming, and may receive and/or process sensor data received from one or more body data sensors such as electrodes 125-1, 125-2, 125-3, or heart rate sensor 130. The controller 210 is capable of affecting substantially all functions of the IMD 200.

The controller 210 may comprise various components, such as a processor 215, a memory 217, etc. The processor 215 may comprise one or more micro controllers, micro processors, etc., that are capable of executing a variety of software components. The processor may receive, pre-condition and/or condition sensor signals, and may control operations of other components of the IMD 200, such as stimulation unit 220, seizure detection module 240, logic unit 250, communication unit, 260, and electrode polarity reversal unit 280. The memory 217 may comprise various memory portions, where a number of types of data (e.g., internal data, external data instructions, software codes, status data, diagnostic data, etc.) may be stored. The memory 217 may store various tables or other database content that could be used by the IMD 200 to implement the override of normal operations. The memory 217 may comprise random access memory (RAM) dynamic random access memory (DRAM), electrically erasable programmable read-only memory (EEPROM), flash memory, etc.

The IMD 200 may also comprise a stimulation unit 220. The stimulation unit 220 is capable of generating and delivering a variety of electrical signal therapy signals to one or more electrodes via leads. The stimulation unit 220 is capable of delivering a programmed, first electrical signal to the leads 122 coupled to the IMD 200. The electrical signal may be delivered to the leads 122 by the stimulation unit 220 based upon instructions from the controller 210. The stimulation unit 220 may comprise various types of circuitry, such as stimulation signal generators, impedance control circuitry to control the impedance “seen” by the leads, and other circuitry that receives instructions relating to the type of stimulation to be performed.

Signals from sensors (electrodes that are used to sense one or more body parameters such as temperature, heart rate, brain activity, etc.) may be provided to the IMD 200. The body signal data from the sensors may be used by a seizure detection algorithm embedded or processed in seizure detection unit 250 to determine whether or not the patient has had an epileptic seizure. The seizure detection algorithm may comprise hardware, software, firmware or combinations thereof, and may operate under the control of the controller 210. Although not shown, additional signal conditioning and filter elements (e.g., amplifiers, D/A converters, etc., may be used to appropriately condition the signal for use by the seizure detection unit 250. Sensors such as heart sensor 130 and kinetic sensor 140 may be used to detect seizures, along with other autonomic, neurologic, or other body data.

The IMD 200 may also comprise an electrode polarity reversal unit 280. The electrode polarity reversal unit 280 is capable of reversing the polarity of electrodes (125-1, 125-2, 125-3) associated with the electrode assembly 125. The electrode polarity reversal unit 280 is shown in more detail in FIG. 3. In preferred embodiments, the electrode polarity reversal unit is capable of reversing electrode polarity rapidly, i.e., in about 10 microseconds or less, and in any event at a sufficiently rapid rate to permit electrode polarities to be changed between adjacent pulses in a pulsed electrical signal.

The IMD 200 may also comprise a power supply 230. The power supply 230 may comprise a battery, voltage regulators, capacitors, etc., to provide power for the operation of the IMD 200, including delivering the stimulation signal. The power supply 230 comprises a power-source battery that in some embodiments may be rechargeable. In other embodiments, a non-rechargeable battery may be used. The power supply 230 provides power for the operation of the IMD 200, including electronic operations and the stimulation function. The power supply 230 may comprise a lithium/thionyl chloride cell or a lithium/carbon monofluoride (LiCFx) cell. Other battery types known in the art of implantable medical devices may also be used.

The IMD 200 also comprises a communication unit 260 capable of facilitating communications between the IMD 200 and various devices. In particular, the communication unit 260 is capable of providing transmission and reception of electronic signals to and from an external unit 270. The external unit 270 may be a device that is capable of programming various modules and stimulation parameters of the IMD 200. In one embodiment, the external unit 270 comprises a computer system that is capable of executing a data-acquisition program. The external unit 270 may be controlled by a healthcare provider, such as a physician, at a base station in, for example, a doctor's office. The external unit 270 may be a computer, preferably a handheld computer or PDA, but may alternatively comprise any other device that is capable of electronic communications and programming. The external unit 270 may download various parameters and program software into the IMD 200 for programming the operation of the implantable device. The external unit 270 may also receive and upload various status conditions and other data from the IMD 200. The communication unit 260 may be hardware, software, firmware, and/or any combination thereof. Communications between the external unit 270 and the communication unit 260 may occur via a wireless or other type of communication, illustrated generally by line 275 in FIG. 2.

In one embodiment, the communication unit 260 can transmit a log of stimulation data and/or seizure detection data to the patient, a physician, or another party.

In one embodiment, a method of treating an epileptic seizure is provided that involves providing simultaneously both a first electrical signal to a main trunk of a vagus nerve and a second electrical signal to a cardiac branch of the vagus nerve. The method may be achieved using only two electrodes by providing a polarity reversal unit to rapidly reverse the polarity of the first and second electrodes. The method includes sensing a cardiac signal and a kinetic signal of the patient, and detecting a seizure event with a seizure detection algorithm. The timing of pulses for the first and second electrical signals may be determined by controller 210 in conjunction with stimulation unit 220. When beneficial, steps to avoid collisions of actions potentials travelling in opposite directions may be implemented, while steps to promote collisions may be taken when clinically indicated.

To provide simultaneous first and second electrical signals to the main trunk and cardiac branch, a pulse of the first electrical signal is generated with the electrical signal generator 110 and applied to the main trunk of the vagus nerve using the first electrode 125-1 as a cathode and the second electrode as an anode. The polarity of the electrodes is then reversed by the polarity reversal unit 280, yielding a configuration wherein the first electrode is an anode and the second electrode is a cathode. A pulse of the second electrical signal (having the appropriate pulse width and current) is generated and applied (under appropriate timing control by controller 110 and stimulation unit 220) to the cardiac branch of the vagus nerve using the second electrode 125-2 as a cathode and first electrode 125-1 as an anode. The polarities of the electrodes may then be reversed by polarity reversal unit 280 under the control of controller 210, and another pulse of the first electrical signal may be generated and applied to the main trunk under timing and parameter control of controller 210 and stimulation unit 220. By rapidly (within a few microseconds) switching the polarities of the electrodes 125-1 and 125-2, the first and second electrical signals may be interleaved and provided simultaneously to the main trunk and cardiac branches of the vagus nerve.

The IMD 200 is capable of delivering stimulation that can be contingent, periodic, random, coded, and/or patterned. The stimulation signals may comprise an electrical stimulation frequency of approximately 0.1 to 2500 Hz. The stimulation signals may comprise a pulse width in the range of approximately 1-2000 micro-seconds. The stimulation signals may comprise current amplitude in the range of approximately 0.1 mA to 10 mA. Appropriate precautions may be taken to avoid delivering injurious current densities to target neural tissues, e.g., by selecting current, voltage, frequency, pulse width, on-time and off-time parameters to maintain current density below thresholds for damaging tissues.

The IMD 200 may also comprise a magnetic field detection unit 290. The magnetic field detection unit 290 is capable of detecting magnetic and/or electromagnetic fields of a predetermined magnitude. Whether the magnetic field results from a magnet placed proximate to the IMD 200, or whether it results from a substantial magnetic field encompassing an area, the magnetic field detection unit 290 is capable of informing the IMD of the existence of a magnetic field. The changeable electrode polarity stimulation described herein may be activated, deactivated, or alternatively activated or deactivated using a magnetic input.

The magnetic field detection unit 290 may comprise various sensors, such as a Reed Switch circuitry, a Hall Effect sensor circuitry, and/or the like. The magnetic field detection unit 290 may also comprise various registers and/or data transceiver circuits that are capable of sending signals that are indicative of various magnetic fields, the time period of such fields, etc. In this manner, the magnetic field detection unit 290 is capable of detecting whether the detected magnetic field relates to an input to implement a particular first or second electrical signal (or both) for application to the main trunk of cardiac branches, respectively, of the vagus nerve.

One or more of the blocks illustrated in the block diagram of the IMD 200 in FIG. 2, may comprise hardware units, software units, firmware units, or any combination thereof. Additionally, one or more blocks illustrated in FIG. 2 may be combined with other blocks, which may represent circuit hardware units, software algorithms, etc. Additionally, one or more of the circuitry and/or software units associated with the various blocks illustrated in FIG. 2 may be combined into a programmable device, such as a field programmable gate array, an ASIC device, etc.

FIG. 3 shows in greater detail an electrode polarity reversal unit 280 (FIG. 2) in one embodiment. The electrode polarity reversal unit 280 comprises an electrode configuration switching unit 340, which includes a switching controller 345. The switching controller 345 transmits signals to one or more switches, generically, n switches 330(1), 330(2), . . . 330(n) which effect the switching of the configuration of two or more electrodes, generically, n electrodes 125(1), 125(2), . . . 125(n). Although FIG. 3 shows equal numbers of switches 330 and electrodes 125, persons of skill in the art having the benefit of the present disclosure will understand that the number of switches 330 and their connections with the various electrodes 125 can be varied as a matter of routine optimization. A switching timing unit 333 can signal to the electrode configuration switching unit 340 that a desired time for switching the electrode configuration has been reached.

Instructions for implementing two or more stimulation regimens, which may include at least one open-loop electrical signal and at least one closed-loop electrical signal, may be stored in the IMD 200. These stimulation signals may include data relating to the type of stimulation signal to be implemented. In one embodiment, an open-loop signal may be applied to generate action potentials for modulating the brain of the patient, and a closed-loop signal may be applied to generate either action potentials for slowing the heart rate of the patient, or both action potentials to modulate the brain of the patient as well as action potentials for slowing the heart rate of the patient. In some embodiments, the open-loop and closed-loop signals may be provided to different target portions of a vagus nerve of the patient by switching the polarity of two or more electrodes using an electrode polarity reversal unit as described in FIG. 3 above. In alternative embodiments, additional electrodes may be provided to generate each of the open-loop and closed-loop signals without electrode switching.

In one embodiment, a first open-loop mode of stimulation may be used to provide an electrical signal to a vagus nerve using a first electrode as a cathode on a main trunk (e.g., 127-1 or 127-3 using electrodes 125-1 or 125-3, respectively) of a vagus nerve, and a second electrode as an anode on either a main trunk (e.g., electrode 125-3, when electrode 125-1 is used as a cathode) or cardiac branch (e.g., electrode 125-2) of a vagus nerve. The first open-loop signal may include a programmed on-time and off-time during which electrical pulses are applied (the on-time) and not-applied (the off-time) in a repeating sequence to the vagus nerve.

A second, closed-loop signal may be provided in response to a detected event (such as an epileptic seizure, particularly when accompanied by an increase in the patient's heart rate) using a different electrode configuration than the first, open-loop signal. In one embodiment, the second, closed-loop signal is applied to a cardiac branch using the second electrode 125-2 as a cathode and the first electrode on the main trunk (e.g., 125-1 or 125-3) as an anode. The second, closed-loop signal may involve generating efferent action potentials on the cardiac branch of the vagus nerve to slow the heart rate. In some embodiments, the first, open-loop signal may be interrupted/suspended in response to the detected event, and only the second, closed-loop signal is applied to the nerve. In other embodiments, the first, open loop signal may not be interrupted when the event is detected, and both the first, open-loop signal and the second, closed-loop signal are applied to the vagus nerve. In another embodiment, a third, closed-loop signal may also be provided in response to the detected event. The third, closed-loop signal may involve an electrical signal using the same electrode configuration as the first, open-loop electrical signal, but may provide a different electrical signal to the main trunk of the vagus nerve than either the first, open-loop signal or the second, closed-loop signal. The first, open-loop signal may be interrupted, terminated or suspended in response to the detected event, and the third, closed-loop signal may be applied to the nerve either alone or with the second, closed-loop signal. In some embodiments, both the second and third closed-loop signals may be provided in response to a detected epileptic seizure by rapidly changing the polarity of the first (125-1) and second (125-2) electrodes from cathode to anode and back, as pulses are provided as part of the second and third electrical signals, respectively. In one embodiment, the third electrical signal may involve modulating the brain by using a main trunk electrode (e.g., upper main trunk electrode 125-1) as a cathode and another electrode (e.g., cardiac branch electrode 125-2 or lower main trunk electrode 125-3) as an anode. The third electrical signal may comprise, for example, a signal that is similar to the first electrical signal but which provides a higher electrical current than the first electrical signal, and for a longer duration than the first signal or for a duration that is adaptively determined based upon a sensed body signal (in contrast, for example, to a fixed duration of the first electrical signal determined by a programmed on-time). By rapidly changing polarity of the electrodes, pulses for each of the second and third electrical signals may be provided such that the second and third signals are provided simultaneously to the cardiac branch and main trunk of the vagus nerve. In other embodiments, the first, second and third electrical signals may be provided sequentially rather than simultaneously.

In some embodiments, one or more of the first, second and third electrical signals may comprise a microburst signal, as described more fully in U.S. patent application Ser. Nos. 11/693,421, 11/693,451, and 11/693,499, each filed Mar. 29, 2007 and each hereby incorporated by reference herein in their entirety.

In one embodiment, each of a plurality of stimulation regimens may respectively relate to a particular disorder, or to particular events characterizing the disorder. For example, different electrical signals may be provided to one or both of the main trunk and cardiac branches of the vagus nerve depending upon what effects accompany the seizure. In a particular embodiment, a first open-loop signal may be provided to the patient in the absence of a seizure detection, while a second, closed-loop signal may be provided when a seizure is detected based on a first type of body movement of the patient as detected by, e.g., an accelerometer, a third, closed-loop signal may be provided when the seizure is characterized by a second type of body movement, a fourth, closed-loop signal may be provided when the seizure is characterized by an increase in heart rate, a fifth, closed-loop signal may be provided when the seizure is characterized by a decrease in heart rate, and so on. More generally, stimulation of particular branches or main trunk targets of a vagus nerve may be provided based upon different body signals of the patient. In some embodiments, additional therapies may be provided based on different events that accompany the seizure, e.g., stimulation of a trigeminal nerve or providing a drug therapy to the patient through a drug pump. In one embodiment, different regimens relating to the same disorder may be implemented to accommodate improvements or regressions in the patient's present condition relative to his or her condition at previous times. By providing flexibility in electrode configurations nearly instantaneously, the present invention greatly expands the range of adjustments that may be made to respond to changes in the patient's underlying medical condition.

The switching controller 345 may be a processor that is capable of receiving data relating to the stimulation regimens. In an alternative embodiment, the switching controller may be a software or a firmware module. Based upon the particulars of the stimulation regimens, the switching timing unit 333 may provide timing data to the switching controller 345. The first through nth switches 330(1-n) may be electrical devices, electro-mechanical devices, and/or solid state devices (e.g., transistors).

FIG. 4 shows one embodiment of a method of treating a patient having epilepsy according to the present invention. In this embodiment, a first electrode is coupled to a main trunk of a vagus nerve of the patient (410) and a second electrode is coupled to a cardiac branch of the vagus nerve (420). An electrical signal generator is coupled to the first and second electrodes (430).

The method further involves receiving at least one body data stream of the patient (440). The data may be sensed by a sensor such as heart rate sensor 130 (FIG. 1A) or a sensor that is an integral part of, or coupled to, an IMD 200 (FIG. 2) such as electrical pulse generator 110 (FIG. 1A), and the IMD may also receive the data from the sensor. The at least one body data stream is then analyzed using a seizure detection algorithm (450), and the seizure detection algorithm determines whether or not the patient has had an epileptic seizure (460).

If the algorithm indicates that the patient has not had an epileptic seizure, the method comprises applying a first electrical signal from the electrical signal generator to the main trunk of a vagus nerve using the first electrode as a cathode (470). In one embodiment, applying the first electrical signal comprises continuing to apply a programmed, open-loop electrical signal periodically to the main trunk of the vagus nerve according a programmed on-time and off-time.

If the algorithm indicates that the patient has had an epileptic seizure, the method comprises applying a second electrical signal from the electrical signal generator to the cardiac branch of the vagus nerve using the second electrode as a cathode (480). Depending upon which electrical signal (first or second) is applied, the method may involve changing the polarity of one or both of the first electrode and the second electrode. In one embodiment, the method may comprise suspending the first electrical and applying the second electrical signal. In one embodiment, the method comprises continuing to receive at least one body data stream of the patient at 440 after determining whether or not the patient has had an epileptic seizure.

In an alternative embodiment, if the seizure detection algorithm indicates that the patient has had an epileptic seizure, both the first electrical signal and the second electrical signal are applied to the main trunk and cardiac branches of a vagus nerve of the patient, respectively, at step 480. In a specific implementation of the alternative embodiment, pulses of the first and second electrical signal are applied to the main trunk and cardiac branch of the vagus nerve under the control of controller 210 by rapidly changing the polarity of the first and second electrodes using the electrode polarity reversal unit 280 to apply the first electrical signal to the main trunk using the first electrode as a cathode and the second electrode as an anode, changing the polarity of the first and second electrodes, and applying the second electrical signal to the cardiac branch using the second electrode as a cathode and the first electrode as an anode. Additional pulses for each signal may be similarly applied by rapidly changing the polarity of the electrodes.

In some embodiments, the first electrical signal and the second electrical signal are applied unilaterally, i.e., to a vagal main trunk and a cardiac branch on the same side of the body. In other embodiments, the first and second electrical signals are applied bilaterally, i.e., the second electrical signal is applied to a cardiac branch on the opposite side of the body from the main vagal trunk to which the first electrical signal is applied. In one embodiment, the first electrical signal is applied to a left main trunk to minimize cardiac effects of the first electrical signal, and the second electrical signal is applied to a right cardiac branch, which modulates the sinoatrial node of the heart to maximize cardiac effects of the second electrical signal.

FIG. 5 is a flow diagram of another method of treating a patient having epilepsy according to the present invention. A sensor is used to sense a cardiac signal and a kinetic signal of the patient (540). In a particular embodiment, the cardiac sensor may comprise an electrode pair for sensing an ECG (electrocardiogram) or heart beat signal, and the kinetic signal may comprise a triaxial accelerometer to detect motion of at least a portion of the patient's body. The method further comprises analyzing at least one of the cardiac signal and the kinetic signal using seizure detection algorithm (550), and the output of the algorithm is used to determine whether at least one of the cardiac signal and the kinetic signal indicate that the patient has had an epileptic seizure (560).

If the patient has not had an epileptic seizure, the method comprises applying a first electrical signal to a main trunk of a vagus nerve of the patient using a first electrode, coupled to the main trunk, as a cathode (580). In one embodiment, the first electrical signal is an open-loop electrical signal having an on-time and off-time.

If the patient has had an epileptic seizure, a determination is made whether the seizure is characterized by an increase in the patient's heart rate (570). If the seizure is not characterized by an increase in the patient's heart rate, the method comprises applying the first electrical signal to the main trunk of a vagus nerve using the first electrode as a cathode (580). In one embodiment, the cathode comprises an upper main trunk electrode 125-1 and the anode is selected from a cardiac branch electrode 125-2 and a lower main trunk electrode 125-3. Conversely, if the seizure is characterized by an increase in the patient's heart rate, the method comprises applying a second electrical signal to a cardiac branch of a vagus nerve of the patient using a second electrode, coupled to the cardiac branch, as a cathode (590). The anode is an upper main trunk electrode 125-1 or a lower main trunk electrode 125-3. In one embodiment, the method may comprise suspending the first electrical and applying the second electrical signal.

The method then continues the sensing of the cardiac and kinetic signals of the patient (540) and resumes the method as outlined in FIG. 5.

FIG. 6 is a flow diagram of a further method of treating a patient having epilepsy according to the present invention. The method includes applying a first, open-loop electrical signal to a main trunk of a vagus nerve (610). The open-loop signal is characterized by an off-time in which electrical pulses are applied to the nerve, and an off-time in which electrical pulses are not applied to the nerve.

A sensor is used to sense at least one body signal of the patient (620), and a determination is made whether the at least one body signal indicates that the patient has had an epileptic seizure (630). If the patient has not had a seizure, the method continues applying the first, open-loop electrical signal to a main trunk of a vagus nerve (610). If the patient has had an epileptic seizure, a determination is made whether the seizure is characterized by an increase in the patient's heart rate (640). In one embodiment, the increase in heart rate is measured from a baseline heart rate existing prior to the seizure, e.g., a median heart rate for a prior period such as the 300 beats prior to the detection of the seizure event, or the 5 minutes prior to the detection of the seizure.

If the seizure is not characterized by an increase in the patient's heart rate, the method comprises applying a second, closed-loop electrical signal to the main trunk of the vagus nerve 650). In one embodiment, the second, closed-loop electrical signal is the same signal as the open-loop electrical signal, except that the second signal (as defined, e.g., by a current intensity, a pulse frequency, a pulse width and an on-time) is applied at a time different from the programmed timing of the first electrical signal. For example, if the first electrical signal comprises an on-time of 30 seconds and an off-time of 5 minutes, but a seizure is detected 1 minute after the end of a programmed on-time, the second electrical signal may comprise applying a 30 second pulse burst at the same current intensity, frequency, and pulse width as the first signal, but four minutes earlier than would have occurred absent the detected seizure. In another embodiment, the second, closed-loop electrical signal is a different signal than the first, open-loop electrical signal, and the method may also comprise suspending the first electrical before applying the second electrical signal. For example, the second, closed-loop electrical signal may comprise a higher current intensity, frequency, pulse width and/or on-time than the first, open-loop electrical signal, and may not comprise an off-time (e.g., the second electrical signal may be applied for a predetermined duration independent of the on-time of the first, open-loop electrical signal, such as a fixed duration of 1 minute, or may continue for as long as the body signal indicates the presence of the seizure event).

Returning to FIG. 6, if the seizure is characterized by an increase in the patient's heart rate, the method comprises applying a third, closed-loop electrical signal to a cardiac branch of a vagus nerve to reduce the patient's heart rate (660). The method may comprise suspending the first electrical as well as applying the third, closed-loop electrical signal. In one embodiment of the invention, each of the first, open-loop electrical signal, the second, closed-loop electrical signal, and the third, closed-loop electrical signal are applied unilaterally (i.e., to vagus nerve structures on the same side of the body) to the main trunk and cardiac branch of the vagus nerve. For example, the first, open-loop electrical signal and the second, closed-loop electrical signal may be applied to a left main trunk of the patient's cervical vagus nerve, and the third, closed-loop electrical signal may be applied to the left cardiac branch of the vagus nerve. Similarly, the first, second and third electrical signals may all be applied to the right vagus nerve of the patient. In alternative embodiments, one or more of the first, second and third electrical signals may be applied bilaterally, i.e., one of the first, second and third electrical signals is applied to a vagal structure on the opposite side of the body from the other two signals. For example, in a particular embodiment the first, open-loop signal and the second, closed-loop signal may be applied to a left main trunk of the patient's cervical vagus nerve, and the third, closed-loop electrical signal may be applied to a right cardiac branch of the patient's vagus nerve. Because the right cardiac branch modulates the sinoatrial node of the patient's heart, which is the heart's “natural pacemaker,” the third electrical signal may have more pronounced effect in reducing the patient's heart rate if applied to the right cardiac branch.

After applying one of the second (650) and third (660) electrical signals to a vagus nerve of the patient, the method then continues sensing at least one body signal of the patient (620) and resumes the method as outlined in FIG. 6.

In the methods depicted in FIGS. 4-6, one or more of the parameters defining the first, second, and third electrical signals (e.g., number of pulses, pulse frequency, pulse width, On time, Off time, interpulse interval, number of pulses per burst, or interburst interval, among others) can be changed by a healthcare provided using a programmer 150.

FIG. 7 is a flow diagram of a method of treating patients having seizures accompanied by increased heart rate. In one embodiment, tachycardia is defined as a neurogenic increase in heart rate, that is, an elevation in heart rate that occurs in the absence of motor activity or that if associated with motor activity, the magnitude of the increase in heart rate is larger than that caused by motor activity alone. In one embodiment, a body signal is acquired (710). The body signal may comprise one or more body signals that may be altered, changed or influenced by an epileptic seizure. As non-limiting examples, the body signal may comprise one or more of a cardiac signal such as heart rate, heart rate variability, or EKG complex morphology, a kinetic signal such as an accelerometer signal, a postural signal or body position signal), blood pressure, blood oxygen concentration, skin resistivity or conductivity, pupil dilation, eye movement, EEG, reaction time or other body signals. The body signal may be a real-time signal or a stored signal for delayed or later analysis. It may be acquired, for example, from a sensor element (e.g., coupled to a processor), from a storage device in which the signal data is stored.

The method further comprises determining whether or not the patient has had a seizure accompanied by an increase in heart rate (720). In one embodiment, the method comprises a seizure detection algorithm that analyzes the acquired body signal data and determines whether or not a seizure has occurred. In a particular embodiment, the method comprises an algorithm that analyzes one or more of a cardiac signal, a kinetic signal, a cognitive signal, blood pressure, blood oxygen concentration, skin resistivity or conductivity, pupil dilation, and eye movement to identify changes in the one or more signals that indicate a seizure has occurred. The method may comprise an output signal or data flag that may be asserted or set when the detection algorithm determines from the body signal(s) that the patient has had a seizure.

The method also comprises determining (720) whether or not the seizure is accompanied by an increase in heart rate. In one embodiment, the body data signal comprises a heart beat signal that may be analyzed to determine heart rate. In some embodiments, the heart beat signal may be used by the seizure detection algorithm to determine whether a seizure has occurred, while in other embodiments seizures are not detected using heart rate. Regardless of how the seizure is detected, however, the method of FIG. 7 comprises determining whether a detected seizure event is accompanied by an increase in heart rate. The increase may be determined in a variety of ways, such as by an increase in an instantaneous heart rate above a reference heart rate (which may be a predetermined interictal value such as 72 beats per minute (bpm), or a real-time measure of central tendency for a time window, such as a 5 minute median or moving average heart rate). Additional details about identifying increases in heart rate in the context of epileptic seizures are provided in U.S. Pat. Nos. 5,928,272, 6,341,236, 6,587,727, 6,671,556, 6,961,618, 6,920,357, 7,457,665, as well as U.S. patent application Ser. Nos. 12/770,562, 12/771,727, 12/771,783, 12/884,051, 12/886,419, 12/896,525, 13/098,262, and 13/288,886, each of which is hereby incorporated by reference in its entirety herein.

If the body data signal does not indicate that the patient has had a seizure accompanied by tachycardia, the method comprises applying a first electrical signal to a left vagus nerve. If the body signal does indicate that the patient has experienced a seizure accompanied by tachycardia, the method comprises applying a second electrical signal to a right vagus nerve.

Without being bound by theory, it is believed that stimulation of the right vagus nerve, which enervates the right sinoatrial nerve that functions as the heart's natural pacemaker, will have a more prominent effect in slowing the heart rate than stimulation of the left vagus nerve. The present invention takes advantage of this electrical asymmetry of the left and right vagus nerves to minimize the effect of VNS on heart rate except where there is a need for acute intervention to slow the heart rate, i.e., when the patient has experienced and epileptic seizure, and the seizure is accompanied by an increase in heart rate. This may result in, for example, stimulation of the left vagus nerve either when there is no seizure (such as when an open-loop stimulation program off-time has elapsed and the program initiates stimulation in accordance with a programmed signal on-time), or when there is a detected seizure event that is not accompanied by an increase in heart rate (such as absence seizures); and stimulation of the right vagus nerve when there is a detected seizure event accompanied by a heart rate increase. In one embodiment, a programmed, open-loop electrical signal is applied to the left vagus nerve except when an algorithm analyzing the acquired body signal detects a seizure accompanied by a heart rate increase. In response to such a detection, a closed-loop electrical signal is applied to the right vagus nerve to slow the patient's (increased) heart rate. In some embodiments, the response to detecting a seizure accompanied by a heart rate increase may also include interrupting the application of the programmed-open-loop electrical signal to the left vagus nerve. The interrupted open-loop stimulation of the left vagus nerve may be resumed either when the seizure ends or the heart rate returns to a desired, lower heart rate.

In an additional embodiment of the invention, electrode pairs may be applied to each of the left and right vagus nerves of the patient, and used depending upon whether or not seizures accompanied by cardiac changes such as tachycardia are detected. In one such embodiment, a method of treating epilepsy patients may be provided as described below.

A method of treating a patient having epilepsy comprising:

coupling a first set of electrodes and a second set of electrodes to the vagi nerves of the patient, wherein said first electrode set is coupled to a main trunk of the left vagus nerve of the patient, and the second set of electrode is coupled to a main trunk of the right vagus nerve of the patient,

providing an electrical signal generator coupled to the first electrode set and the second electrode set,

receiving at least one body data stream,

analyzing the at least one body data stream using a seizure detection algorithm to determine

whether or not the patient has had an epileptic seizure,

applying a first electrical signal from the electrical signal generator to the main trunk of the left vagus nerve, based on a determination that the patient has had an epileptic seizure without cardiac changes, and

applying a second electrical signal from the electrical signal generator to the main trunk of the right vagus nerve, based on a determination that the patient has had an epileptic seizure.

The particular embodiments disclosed above are illustrative only as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown other than as described in the claims below. It is, therefore, evident that the particular embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.

Claims

1. A method of treating a patient having epilepsy via an implantable medical device which includes an electrical signal generator coupled to a first electrode and a second electrode where the first electrode is coupled to a main trunk of a vagus nerve of the patient and a second electrode is coupled to a cardiac branch of the vagus nerve of the patient, the method comprising: receiving at least one body data stream;analyzing the at least one body data stream using a seizure detection algorithm to determine an epileptic seizure state;applying a first electrical signal from the electrical signal generator to the main trunk of the vagus nerve using the first electrode as a cathode, based on a determination that the epileptic seizure state of the patient is a first state where an epileptic seizure is not detected; andapplying a second electrical signal from the electrical signal generator to the cardiac branch of the vagus nerve using the second electrode as the cathode, based on a determination that the epileptic seizure state of the patient is a second state where the epileptic seizure is detected.
2. The method of claim 1, wherein the second electrical signal is configured to reduce a heart rate of the patient.
3. The method of claim 1, wherein applying the first electrical signal is based on a programmed duty cycle having at least a programmed on-time and a programmed off-time.
4. The method of claim 1, wherein based on the determination that the epileptic seizure state of the patient is the second state where the epileptic seizure is detected, the method further comprises identifying an increase in a patient's heart rate, and applying the second electrical signal to reduce the patient's heart rate.
5. The method of claim 4, further comprising: sensing the patient's heart rate in response to applying the second electrical signal, and interrupting the second electrical signal if a decrease in the patient's heart rate reaches a lower heart rate threshold.
6. The method of claim 4 further comprising: sensing the patient's heart rate in response to applying the second electrical signal, and modifying the second electrical signal to maintain the patient's heart rate between an upper rate threshold and the lower heart rate threshold.
7. The method of claim 1 wherein the first electrode is proximal to a brain of the patient relative to the second electrode, wherein applying the first electrical signal comprises using the first electrode as the cathode and the second electrode as an anode, and wherein applying the second electrical signal comprises using the second electrode as the cathode and first electrode as the anode to reduce a patient's heart rate.
8. The method of claim 7, wherein the implantable medical device includes a polarity reversal unit capable of reversing a polarity of the first electrode and the second electrode to apply the first electrical signal and the second electrical signal.
9. The method of claim 1, wherein the implantable medical device includes a third electrode coupled to the main trunk of the vagus nerve and to a programmable signal generator, wherein applying the first electrical signal comprises applying the first electrical signal to the vagus nerve using the first electrode as the cathode and the third electrode as an anode.
10. The method of claim 1, wherein at least one of the first electrical signal and the second electrical signal is a microburst electrical signal characterized by having a number of pulses per microburst from 2 pulses to about 25 pulses, an interpulse interval of about 2 msec to about 50 msec, an interburst period of at least 100 msec, and a microburst duration of less than about 1 sec.
11. The method of claim 1, wherein based on the determination that the epileptic seizure state of the patient is the second state where the epileptic seizure is detected, the method further comprises identifying an increase in a patient's heart rate and applying both: the first electrical signal from the electrical signal generator to the main trunk of the vagus nerve using the first electrode as the cathode, andthe second electrical signal from the electrical signal generator to the cardiac branch of the vagus nerve using the second electrode as the cathode.
12. The method of claim 11, wherein the first electrical signal and the second electrical signal are applied to the vagus nerve in at least one of a sequential fashion, a simultaneous fashion, and in alternating and repeating fashion.
13. A method of treating a patient having epilepsy comprising: sensing a cardiac signal and a kinetic signal of the patient; analyzing at least one of the cardiac signal and the kinetic signal;determining whether or not the patient has had an epileptic seizure based on the analyzing;in response to a determination that the patient has had the epileptic seizure, determining whether or not the epileptic seizure is characterized by an increase in a patient's heart rate;applying a first electrical signal to a main trunk of a vagus nerve of the patient using a first electrode as a cathode based on one of: a) a determination that the patient has not had the epileptic seizure, and b) a determination that the patient has had the epileptic seizure that is not characterized by the increase in the patient's heart rate, wherein the first electrode is coupled to the main trunk; andapplying a second electrical signal to a cardiac branch of the vagus nerve of the patient using a second electrode as the cathode based on a determination that the patient has had the epileptic seizure characterized by the increase in the patient's heart rate, wherein the second electrode is coupled to the cardiac branch.
14. The method of claim 13, wherein applying the first electrical signal is based on a programmed duty cycle having at least a programmed on-time and a programmed off-time.
15. The method of claim 13, wherein the second electrical signal is configured to reduce the patient's heart rate.
16. The method of claim 13 further comprising: applying the first electrical signal comprises using the first electrode as the cathode and the second electrode as an anode; andapplying the second electrical signal comprises using the second electrode as the cathode and the first electrode as the anode;wherein the first electrode is proximal to a brain of the patient relative to the second electrode.
17. The method of claim 16 further comprising utilizing a polarity reversal unit capable of reversing a polarity of the first electrode and the second electrode to apply the first electrical signal and the second electrical signal.
18. The method of claim 17 further comprising: applying the first electrical signal at a first point in time based on a determination that the patient has not had the epileptic seizure characterized by the increase in the patient's heart rate,reversing the polarity of the first electrode and the second electrode, andapplying the second electrical signal at a second point in time based on a determination that the patient has had the epileptic seizure characterized by the increase in the patient's heart rate.
19. A method of treating a patient having epilepsy comprising: applying a first electrical signal to a main trunk of a vagus nerve of the patient, wherein the first electrical signal is an open-loop electrical signal having a programmed on-time and a programmed off-time;sensing at least one body signal of the patient, determining a start of an epileptic seizure based on the at least one body signal, determining whether or not the epileptic seizure is characterized by an increase in a patient's heart rate;applying a second, closed-loop electrical signal to the main trunk of the vagus nerve based on a determination that the epileptic seizure is not characterized by the increase in the patient's heart rate; andapplying a third, closed-loop electrical signal to a cardiac branch of the vagus nerve based on a determination that the epileptic seizure is characterized by the increase in the patient's heart rate, wherein the third electrical signal is applied to reduce the patient's heart rate.
20. A method of treating a patient having epilepsy comprising: sensing at least one body signal of the patient;determining whether or not the patient has had an epileptic seizure based on the at least one body signal;sensing a cardiac signal of the patient;in response to a determination that the patient has had the epileptic seizure, determining whether or not the epileptic seizure is characterized by an increase in a patient's heart rate;applying a first electrical signal to a left vagus nerve of the patient using a first electrode as a cathode based on one of a) a determination that the patient has not had the epileptic seizure, and b) a determination that the patient has had the epileptic seizure that is not characterized by the increase in the patient's heart rate, wherein the first electrode is coupled to the left vagus nerve; andapplying a second electrical signal to a right vagus nerve of the patient using a second electrode as the cathode based on a determination that the patient has had the epileptic seizure characterized by the increase in the patient's heart rate, wherein the second electrode is coupled to the right vagus nerve.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of and claims priority to U.S. patent application Ser. No. 12/020,097 filed Jan. 25, 2008 and U.S. patent application Ser. No. 12/020,195 filed Jan. 25, 2008, both of which are incorporated herein by reference in their entirety.

US Referenced Citations (543)

Number	Name	Date	Kind
3760812	Timm et al.	Sep 1973	A
3796221	Hagfors	Mar 1974	A
4107469	Jenkins	Aug 1978	A
4305402	Katims	Dec 1981	A
4338945	Kosugi et al.	Jul 1982	A
4424812	Lesnick	Jan 1984	A
4431000	Butler et al.	Feb 1984	A
4459989	Borkan	Jul 1984	A
4503863	Katims	Mar 1985	A
4541432	Molina-Negro et al.	Sep 1985	A
4573481	Bullara	Mar 1986	A
4577316	Schiff	Mar 1986	A
4590946	Loeb	May 1986	A
4592339	Kuzmak et al.	Jun 1986	A
4606349	Livingston et al.	Aug 1986	A
4608985	Crish et al.	Sep 1986	A
4612934	Borkan	Sep 1986	A
4625308	Kim et al.	Nov 1986	A
4628942	Sweeney et al.	Dec 1986	A
4649936	Ungar et al.	Mar 1987	A
4702254	Zabara	Oct 1987	A
4793353	Borkan	Dec 1988	A
4867164	Zabara	Sep 1989	A
4920979	Bullara	May 1990	A
4949721	Toriu et al.	Aug 1990	A
4977895	Tannenbaum	Dec 1990	A
5025807	Zabara	Jun 1991	A
5081987	Nigam	Jan 1992	A
5154172	Terry, Jr. et al.	Oct 1992	A
5179950	Stanislaw	Jan 1993	A
5188104	Wernicke et al.	Feb 1993	A
5205285	Baker, Jr.	Apr 1993	A
5215086	Terry, Jr. et al.	Jun 1993	A
5222494	Baker, Jr.	Jun 1993	A
5231988	Wernicke et al.	Aug 1993	A
5235980	Varrichio et al.	Aug 1993	A
5263480	Wernicke et al.	Nov 1993	A
5269303	Wernicke et al.	Dec 1993	A
5299569	Wernicke et al.	Apr 1994	A
5330507	Schwartz	Jul 1994	A
5330515	Rutecki et al.	Jul 1994	A
5334221	Bardy	Aug 1994	A
5335657	Terry, Jr. et al.	Aug 1994	A
5354320	Schaldach et al.	Oct 1994	A
5411531	Hill et al.	May 1995	A
5411540	Edell et al.	May 1995	A
5423872	Cigaina	Jun 1995	A
5507784	Hill et al.	Apr 1996	A
5522862	Testerman et al.	Jun 1996	A
5522865	Schulman et al.	Jun 1996	A
5531778	Maschino et al.	Jul 1996	A
5540730	Terry, Jr. et al.	Jul 1996	A
5540734	Zabara	Jul 1996	A
5571150	Wernicke et al.	Nov 1996	A
5601617	Loeb et al.	Feb 1997	A
5611350	John	Mar 1997	A
5645570	Corbucci	Jul 1997	A
5651378	Matheny et al.	Jul 1997	A
5658318	Stroetmann et al.	Aug 1997	A
5690681	Geddes et al.	Nov 1997	A
5690688	Noren et al.	Nov 1997	A
5690691	Chen et al.	Nov 1997	A
5700282	Zabara	Dec 1997	A
5702428	Tippey et al.	Dec 1997	A
5702429	King	Dec 1997	A
5707400	Terry, Jr. et al.	Jan 1998	A
5755750	Petruska et al.	May 1998	A
5792212	Weijand	Aug 1998	A
5800474	Benabid et al.	Sep 1998	A
5814092	King	Sep 1998	A
5836994	Bourgeois	Nov 1998	A
5861014	Familoni	Jan 1999	A
5913882	King	Jun 1999	A
5916239	Geddes et al.	Jun 1999	A
5928272	Adkins et al.	Jul 1999	A
5941906	Barreras, Sr. et al.	Aug 1999	A
5995868	Dorfmeister et al.	Nov 1999	A
6002966	Loeb et al.	Dec 1999	A
6016449	Fischell et al.	Jan 2000	A
6041258	Cigaina et al.	Mar 2000	A
6083249	Familoni	Jul 2000	A
6101412	Duhaylongsod	Aug 2000	A
6104955	Bourgeois	Aug 2000	A
6104956	Naritoku et al.	Aug 2000	A
6115628	Stadler et al.	Sep 2000	A
6132361	Epstein et al.	Oct 2000	A
6141590	Renirie et al.	Oct 2000	A
6161044	Silverstone	Dec 2000	A
6167311	Rezai	Dec 2000	A
6175764	Loeb et al.	Jan 2001	B1
6188929	Giordano	Feb 2001	B1
6219580	Faltys et al.	Apr 2001	B1
6221908	Kilgard et al.	Apr 2001	B1
6238423	Bardy	May 2001	B1
6249704	Maltan et al.	Jun 2001	B1
6253109	Gielen	Jun 2001	B1
6266564	Hill et al.	Jul 2001	B1
6295472	Rubenstein et al.	Sep 2001	B1
6304775	Iasemidis et al.	Oct 2001	B1
6308102	Sieracki	Oct 2001	B1
6324421	Stadler et al.	Nov 2001	B1
6327503	Familoni	Dec 2001	B1
6339725	Naritoku et al.	Jan 2002	B1
6341236	Osorio et al.	Jan 2002	B1
6353762	Baudino et al.	Mar 2002	B1
6356788	Boveja	Mar 2002	B2
6358203	Bardy	Mar 2002	B2
6366813	DiLorenzo	Apr 2002	B1
6366814	Boveja et al.	Apr 2002	B1
6374140	Rise	Apr 2002	B1
6381493	Stadler et al.	Apr 2002	B1
6381496	Meadows et al.	Apr 2002	B1
6381499	Taylor et al.	Apr 2002	B1
6418344	Rezai et al.	Jul 2002	B1
6425852	Epstein et al.	Jul 2002	B1
6438423	Rezai et al.	Aug 2002	B1
6449512	Boveja	Sep 2002	B1
6453199	Kobozev	Sep 2002	B1
6459936	Fischell et al.	Oct 2002	B2
6463328	John	Oct 2002	B1
6466822	Pless	Oct 2002	B1
6473639	Fischell et al.	Oct 2002	B1
6473644	Terry, Jr. et al.	Oct 2002	B1
6477417	Levine	Nov 2002	B1
6477418	Plicchi et al.	Nov 2002	B2
6480743	Kirkpatrick et al.	Nov 2002	B1
6484132	Hively et al.	Nov 2002	B1
6487446	Hill et al.	Nov 2002	B1
6505074	Boveja et al.	Jan 2003	B2
6522928	Whitehurst et al.	Feb 2003	B2
6532388	Hill et al.	Mar 2003	B1
6549804	Osorio et al.	Apr 2003	B1
6556868	Naritoku et al.	Apr 2003	B2
6564102	Boveja	May 2003	B1
6565503	Leysieffer et al.	May 2003	B2
6579280	Kovach et al.	Jun 2003	B1
6587719	Barrett et al.	Jul 2003	B1
6587724	Mann	Jul 2003	B2
6587726	Lurie et al.	Jul 2003	B2
6587727	Osorio et al.	Jul 2003	B2
6591138	Fischell et al.	Jul 2003	B1
6594524	Esteller et al.	Jul 2003	B2
6600953	Flesler et al.	Jul 2003	B2
6600955	Zierhofer	Jul 2003	B1
6609025	Barrett et al.	Aug 2003	B2
6609030	Rezai et al.	Aug 2003	B1
6609031	Law et al.	Aug 2003	B1
6610713	Tracey	Aug 2003	B2
6611715	Boveja	Aug 2003	B1
6612983	Marchal	Sep 2003	B1
6615081	Boveja	Sep 2003	B1
6615084	Cigaina	Sep 2003	B1
6615085	Boveja	Sep 2003	B1
6622038	Barrett et al.	Sep 2003	B2
6622041	Terry, Jr. et al.	Sep 2003	B2
6622047	Barrett et al.	Sep 2003	B2
6628987	Hill et al.	Sep 2003	B1
6656960	Puskas	Dec 2003	B2
6662053	Borkan	Dec 2003	B2
6668191	Boveja	Dec 2003	B1
6671547	Lyster et al.	Dec 2003	B2
6671555	Gielen et al.	Dec 2003	B2
6671556	Osorio et al.	Dec 2003	B2
6684104	Gordon et al.	Jan 2004	B2
6684105	Cohen et al.	Jan 2004	B2
6690973	Hill et al.	Feb 2004	B2
6690974	Archer et al.	Feb 2004	B2
6708064	Rezai	Mar 2004	B2
6721603	Zabara et al.	Apr 2004	B2
6731979	MacDonald	May 2004	B2
6731986	Mann	May 2004	B2
6754536	Swoyer et al.	Jun 2004	B2
6760626	Boveja	Jul 2004	B1
6764498	Mische	Jul 2004	B2
6768969	Nikitin et al.	Jul 2004	B1
6775573	Schuler et al.	Aug 2004	B2
6793670	Osorio et al.	Sep 2004	B2
6819956	DiLorenzo	Nov 2004	B2
6826428	Chen et al.	Nov 2004	B1
6832114	Whitehurst et al.	Dec 2004	B1
6853862	Marchal et al.	Feb 2005	B1
6885888	Rezai	Apr 2005	B2
6895278	Gordon	May 2005	B1
6904390	Nikitin et al.	Jun 2005	B2
6907295	Gross et al.	Jun 2005	B2
6920357	Osorio et al.	Jul 2005	B2
6934580	Osorio et al.	Aug 2005	B1
6944501	Pless	Sep 2005	B1
6961618	Osorio et al.	Nov 2005	B2
7006859	Osorio et al.	Feb 2006	B1
7006872	Gielen et al.	Feb 2006	B2
7050856	Sypulkowski	May 2006	B2
7054686	MacDonald	May 2006	B2
7146217	Firlik et al.	Dec 2006	B2
7167750	Knudson et al.	Jan 2007	B2
7177678	Osorio et al.	Feb 2007	B1
7188053	Nikitin et al.	Mar 2007	B2
7204833	Osorio et al.	Apr 2007	B1
7209787	DiLorenzo	Apr 2007	B2
7231254	DiLorenzo	Jun 2007	B2
7236830	Gliner	Jun 2007	B2
7236831	Firlik et al.	Jun 2007	B2
7242983	Frei et al.	Jul 2007	B2
7242984	DiLorenzo	Jul 2007	B2
7340302	Falkenberg et al.	Mar 2008	B1
20010034541	Lyden	Oct 2001	A1
20010037220	Merry et al.	Nov 2001	A1
20020052539	Haller et al.	May 2002	A1
20020065509	Lebel et al.	May 2002	A1
20020072782	Osorio et al.	Jun 2002	A1
20020082480	Riff et al.	Jun 2002	A1
20020099412	Fischell et al.	Jul 2002	A1
20020099417	Naritoku et al.	Jul 2002	A1
20020116030	Rezai	Aug 2002	A1
20020120310	Linden	Aug 2002	A1
20020133204	Hrdlicka	Sep 2002	A1
20020143368	Bakels et al.	Oct 2002	A1
20020151939	Rezai	Oct 2002	A1
20020153901	Davis et al.	Oct 2002	A1
20020188214	Misczynski et al.	Dec 2002	A1
20030028226	Thompson et al.	Feb 2003	A1
20030040774	Terry, Jr. et al.	Feb 2003	A1
20030055457	MacDonald	Mar 2003	A1
20030074032	Gliner	Apr 2003	A1
20030083716	Nicolelis et al.	May 2003	A1
20030088274	Gliner et al.	May 2003	A1
20030095648	Kaib et al.	May 2003	A1
20030097161	Firlik et al.	May 2003	A1
20030109903	Berrang et al.	Jun 2003	A1
20030125786	Gliner et al.	Jul 2003	A1
20030130706	Sheffield et al.	Jul 2003	A1
20030144711	Pless et al.	Jul 2003	A1
20030144829	Geatz et al.	Jul 2003	A1
20030181954	Rezai	Sep 2003	A1
20030181958	Dobak, III	Sep 2003	A1
20030181959	Dobak	Sep 2003	A1
20030208212	Cigaina	Nov 2003	A1
20030210147	Humbard	Nov 2003	A1
20030212440	Boveja	Nov 2003	A1
20030236558	Whitehurst et al.	Dec 2003	A1
20040006278	Webb et al.	Jan 2004	A1
20040015205	Whitehurst et al.	Jan 2004	A1
20040036377	Mezinis	Feb 2004	A1
20040039424	Merritt et al.	Feb 2004	A1
20040088024	Firlik et al.	May 2004	A1
20040111139	McCreery	Jun 2004	A1
20040112894	Varma	Jun 2004	A1
20040122485	Stahmann et al.	Jun 2004	A1
20040122489	Mazar et al.	Jun 2004	A1
20040133119	Osorio et al.	Jul 2004	A1
20040138516	Osorio et al.	Jul 2004	A1
20040138517	Osorio et al.	Jul 2004	A1
20040138518	Rise et al.	Jul 2004	A1
20040138647	Osorio et al.	Jul 2004	A1
20040138711	Osorio et al.	Jul 2004	A1
20040147969	Mann et al.	Jul 2004	A1
20040147992	Bluger et al.	Jul 2004	A1
20040153129	Pless et al.	Aug 2004	A1
20040158119	Osorio et al.	Aug 2004	A1
20040158165	Yonce et al.	Aug 2004	A1
20040167583	Knudson et al.	Aug 2004	A1
20040167587	Thompson	Aug 2004	A1
20040172085	Knudson et al.	Sep 2004	A1
20040172088	Knudson et al.	Sep 2004	A1
20040172089	Whitehurst et al.	Sep 2004	A1
20040172091	Rezai	Sep 2004	A1
20040172094	Cohen et al.	Sep 2004	A1
20040176812	Knudson et al.	Sep 2004	A1
20040176831	Gliner et al.	Sep 2004	A1
20040193231	David et al.	Sep 2004	A1
20040199146	Rogers et al.	Oct 2004	A1
20040199187	Loughran	Oct 2004	A1
20040199212	Fischell et al.	Oct 2004	A1
20040210270	Erickson	Oct 2004	A1
20040210274	Bauhahn et al.	Oct 2004	A1
20040249302	Donoghue et al.	Dec 2004	A1
20040249416	Yun et al.	Dec 2004	A1
20040260346	Overall et al.	Dec 2004	A1
20040263172	Gray et al.	Dec 2004	A1
20050004615	Sanders	Jan 2005	A1
20050004621	Boveja et al.	Jan 2005	A1
20050010262	Rezai et al.	Jan 2005	A1
20050015128	Rezai et al.	Jan 2005	A1
20050016657	Bluger	Jan 2005	A1
20050020887	Goldberg	Jan 2005	A1
20050021092	Yun et al.	Jan 2005	A1
20050021103	DiLorenzo	Jan 2005	A1
20050021104	DiLorenzo	Jan 2005	A1
20050021105	Firlik et al.	Jan 2005	A1
20050021106	Firlik et al.	Jan 2005	A1
20050021107	Firlik et al.	Jan 2005	A1
20050021118	Genau et al.	Jan 2005	A1
20050027284	Lozano et al.	Feb 2005	A1
20050028026	Shirley et al.	Feb 2005	A1
20050033378	Sheffield et al.	Feb 2005	A1
20050033379	Lozano et al.	Feb 2005	A1
20050038326	Mathurs	Feb 2005	A1
20050038484	Knudson et al.	Feb 2005	A1
20050049515	Misczynski et al.	Mar 2005	A1
20050049655	Boveja et al.	Mar 2005	A1
20050060007	Goetz	Mar 2005	A1
20050060008	Goetz	Mar 2005	A1
20050060009	Goetz	Mar 2005	A1
20050060010	Goetz	Mar 2005	A1
20050065562	Rezai	Mar 2005	A1
20050065573	Rezai	Mar 2005	A1
20050065574	Rezai	Mar 2005	A1
20050065575	Dobak	Mar 2005	A1
20050070971	Fowler et al.	Mar 2005	A1
20050075679	Gliner et al.	Apr 2005	A1
20050075680	Lowry et al.	Apr 2005	A1
20050075681	Rezai et al.	Apr 2005	A1
20050075691	Phillips et al.	Apr 2005	A1
20050075701	Shafer	Apr 2005	A1
20050075702	Shafer	Apr 2005	A1
20050088145	Loch	Apr 2005	A1
20050101873	Misczynski et al.	May 2005	A1
20050102002	Salo et al.	May 2005	A1
20050107753	Rezai et al.	May 2005	A1
20050107842	Rezai	May 2005	A1
20050107858	Bluger	May 2005	A1
20050113705	Fischell et al.	May 2005	A1
20050113744	Donoghue et al.	May 2005	A1
20050119703	DiLorenzo	Jun 2005	A1
20050124901	Misczynski et al.	Jun 2005	A1
20050131467	Boveja	Jun 2005	A1
20050131485	Knudson et al.	Jun 2005	A1
20050131486	Boveja et al.	Jun 2005	A1
20050131493	Boveja et al.	Jun 2005	A1
20050131506	Rezai et al.	Jun 2005	A1
20050137480	Alt et al.	Jun 2005	A1
20050143781	Carbunaru et al.	Jun 2005	A1
20050143786	Boveja	Jun 2005	A1
20050148893	Misczynski et al.	Jul 2005	A1
20050148894	Misczynski et al.	Jul 2005	A1
20050148895	Misczynski et al.	Jul 2005	A1
20050153885	Yun et al.	Jul 2005	A1
20050154425	Boveja et al.	Jul 2005	A1
20050154435	Stern et al.	Jul 2005	A1
20050159789	Brockway et al.	Jul 2005	A1
20050161052	Rezai et al.	Jul 2005	A1
20050165458	Boveja et al.	Jul 2005	A1
20050177192	Rezai et al.	Aug 2005	A1
20050177200	George et al.	Aug 2005	A1
20050177206	North et al.	Aug 2005	A1
20050182389	LaPorte et al.	Aug 2005	A1
20050187590	Boveja et al.	Aug 2005	A1
20050187593	Housworth et al.	Aug 2005	A1
20050187796	Rosenfeld et al.	Aug 2005	A1
20050192644	Boveja et al.	Sep 2005	A1
20050197590	Osorio et al.	Sep 2005	A1
20050222631	Dalal et al.	Oct 2005	A1
20050228693	Webb et al.	Oct 2005	A1
20050240246	Lee et al.	Oct 2005	A1
20050245944	Rezai	Nov 2005	A1
20050245971	Brockway et al.	Nov 2005	A1
20050245990	Roberson	Nov 2005	A1
20050261542	Riehl	Nov 2005	A1
20050267550	Hess et al.	Dec 2005	A1
20050272280	Osypka	Dec 2005	A1
20050277872	Colby, Jr. et al.	Dec 2005	A1
20050277998	Tracey et al.	Dec 2005	A1
20050283200	Rezai et al.	Dec 2005	A1
20050283201	Machado et al.	Dec 2005	A1
20050283208	Von Arx et al.	Dec 2005	A1
20050288600	Zhang et al.	Dec 2005	A1
20050288736	Persen et al.	Dec 2005	A1
20050288760	Machado et al.	Dec 2005	A1
20060009815	Boveja et al.	Jan 2006	A1
20060015153	Gliner et al.	Jan 2006	A1
20060020292	Goetz et al.	Jan 2006	A1
20060020491	Mongeon et al.	Jan 2006	A1
20060041222	Dewing et al.	Feb 2006	A1
20060041223	Dewing et al.	Feb 2006	A1
20060041287	Dewing et al.	Feb 2006	A1
20060047205	Ludomirsky et al.	Mar 2006	A1
20060052843	Elsner et al.	Mar 2006	A1
20060058597	Machado et al.	Mar 2006	A1
20060064133	Von Arx et al.	Mar 2006	A1
20060064134	Mazar et al.	Mar 2006	A1
20060064143	Von Arx et al.	Mar 2006	A1
20060069322	Zhang et al.	Mar 2006	A1
20060074450	Boveja et al.	Apr 2006	A1
20060079936	Boveja et al.	Apr 2006	A1
20060079942	Deno et al.	Apr 2006	A1
20060079945	Libbus	Apr 2006	A1
20060085046	Rezai et al.	Apr 2006	A1
20060094971	Drew	May 2006	A1
20060095081	Zhou et al.	May 2006	A1
20060100667	Machado et al.	May 2006	A1
20060106430	Fowler et al.	May 2006	A1
20060106431	Wyler et al.	May 2006	A1
20060111644	Guttag et al.	May 2006	A1
20060122525	Shusterman	Jun 2006	A1
20060122667	Chavan et al.	Jun 2006	A1
20060122864	Gottesman et al.	Jun 2006	A1
20060135877	Giftakis et al.	Jun 2006	A1
20060135881	Giftakis et al.	Jun 2006	A1
20060155495	Osorio et al.	Jul 2006	A1
20060161459	Rosenfeld et al.	Jul 2006	A9
20060167497	Armstrong et al.	Jul 2006	A1
20060173493	Armstrong et al.	Aug 2006	A1
20060173522	Osorio	Aug 2006	A1
20060190056	Fowler et al.	Aug 2006	A1
20060195155	Firlik et al.	Aug 2006	A1
20060195163	KenKnight et al.	Aug 2006	A1
20060200206	Firlik et al.	Sep 2006	A1
20060212091	Lozano et al.	Sep 2006	A1
20060217780	Gliner et al.	Sep 2006	A1
20060220839	Fifolt et al.	Oct 2006	A1
20060224067	Giftakis et al.	Oct 2006	A1
20060224191	Dilorenzo	Oct 2006	A1
20060241697	Libbus et al.	Oct 2006	A1
20060241725	Libbus et al.	Oct 2006	A1
20060253164	Zhang et al.	Nov 2006	A1
20060253168	Wyler et al.	Nov 2006	A1
20060253169	Wyler et al.	Nov 2006	A1
20060253170	Wyler et al.	Nov 2006	A1
20060253171	Wyler et al.	Nov 2006	A1
20060259095	Wyler et al.	Nov 2006	A1
20060264730	Stivoric et al.	Nov 2006	A1
20060265018	Smith et al.	Nov 2006	A1
20060271409	Rosenfeld et al.	Nov 2006	A1
20060293720	DiLorenzo	Dec 2006	A1
20070156179	Bertolotti et al.	Jan 2007	A1
20070027486	Armstrong	Feb 2007	A1
20070032734	Najafi et al.	Feb 2007	A1
20070032834	Gliner et al.	Feb 2007	A1
20070038262	Kieval et al.	Feb 2007	A1
20070043392	Gliner et al.	Feb 2007	A1
20070055320	Weinand	Mar 2007	A1
20070073150	Gopalsami et al.	Mar 2007	A1
20070073346	Corbucci et al.	Mar 2007	A1
20070073355	Dilorenzo	Mar 2007	A1
20070078491	Siejko et al.	Apr 2007	A1
20070088403	Wyler et al.	Apr 2007	A1
20070088404	Wyler et al.	Apr 2007	A1
20070088405	Jacobson et al.	Apr 2007	A1
20070100278	Frei et al.	May 2007	A1
20070100397	Seeberger et al.	May 2007	A1
20070100398	Sload	May 2007	A1
20070112393	Gliner et al.	May 2007	A1
20070123946	Masoud	May 2007	A1
20070135855	Foshee et al.	Jun 2007	A1
20070142862	Dilorenzo	Jun 2007	A1
20070142873	Esteller et al.	Jun 2007	A1
20070149952	Bland et al.	Jun 2007	A1
20070150011	Meyer et al.	Jun 2007	A1
20070150014	Kramer et al.	Jun 2007	A1
20070150024	Leyde et al.	Jun 2007	A1
20070150025	Dilorenzo et al.	Jun 2007	A1
20070156450	Roehm et al.	Jul 2007	A1
20070156626	Roehm et al.	Jul 2007	A1
20070161919	DiLorenzo	Jul 2007	A1
20070162086	DiLorenzo	Jul 2007	A1
20070167991	DiLorenzo	Jul 2007	A1
20070173901	Reeve	Jul 2007	A1
20070179534	Firlik et al.	Aug 2007	A1
20070179558	Gliner et al.	Aug 2007	A1
20070191905	Errico et al.	Aug 2007	A1
20070208212	DiLorenzo	Sep 2007	A1
20070208390	Von Arx et al.	Sep 2007	A1
20070213785	Osorio et al.	Sep 2007	A1
20070233192	Craig	Oct 2007	A1
20070233193	Craig	Oct 2007	A1
20070233194	Craig	Oct 2007	A1
20070238939	Giftakis et al.	Oct 2007	A1
20070239210	Libbus et al.	Oct 2007	A1
20070239211	Lorincz et al.	Oct 2007	A1
20070239220	Greenhut et al.	Oct 2007	A1
20070244407	Osorio	Oct 2007	A1
20070249953	Frei et al.	Oct 2007	A1
20070249954	Virag et al.	Oct 2007	A1
20070250130	Ball et al.	Oct 2007	A1
20070255147	Drew et al.	Nov 2007	A1
20070255155	Drew et al.	Nov 2007	A1
20070255330	Lee et al.	Nov 2007	A1
20070255337	Lu	Nov 2007	A1
20070260147	Giftakis et al.	Nov 2007	A1
20070260289	Giftakis et al.	Nov 2007	A1
20070265489	Fowler et al.	Nov 2007	A1
20070265508	Sheikhzadeh-Nadjar et al.	Nov 2007	A1
20070265536	Giftakis et al.	Nov 2007	A1
20070272260	Nikitin et al.	Nov 2007	A1
20070282177	Pilz	Dec 2007	A1
20070287931	Dilorenzo	Dec 2007	A1
20070288072	Pascual-Leone et al.	Dec 2007	A1
20070299349	Alt et al.	Dec 2007	A1
20070299473	Matos	Dec 2007	A1
20070299480	Hill	Dec 2007	A1
20080015651	Ettori et al.	Jan 2008	A1
20080015652	Maile et al.	Jan 2008	A1
20080021332	Brainard, III	Jan 2008	A1
20080021341	Harris et al.	Jan 2008	A1
20080021517	Dietrich	Jan 2008	A1
20080021520	Dietrich	Jan 2008	A1
20080027347	Harris et al.	Jan 2008	A1
20080027348	Harris et al.	Jan 2008	A1
20080027515	Harris et al.	Jan 2008	A1
20080033502	Harris et al.	Feb 2008	A1
20080033503	Fowler et al.	Feb 2008	A1
20080033508	Frei et al.	Feb 2008	A1
20080046035	Fowler et al.	Feb 2008	A1
20080046037	Haubrich et al.	Feb 2008	A1
20080046038	Hill et al.	Feb 2008	A1
20080051852	Dietrich et al.	Feb 2008	A1
20080058884	Matos	Mar 2008	A1
20080064934	Frei et al.	Mar 2008	A1
20080071323	Lowry et al.	Mar 2008	A1
20080077028	Schaldach et al.	Mar 2008	A1
20080081962	Miller et al.	Apr 2008	A1
20080082132	Annest et al.	Apr 2008	A1
20080103548	Fowler et al.	May 2008	A1
20080114417	Leyde	May 2008	A1
20080119900	DiLorenzo	May 2008	A1
20080125820	Stahmann et al.	May 2008	A1
20080139870	Gliner et al.	Jun 2008	A1
20080146890	LeBoeuf et al.	Jun 2008	A1
20080146959	Sheffield et al.	Jun 2008	A1
20080161712	Leyde	Jul 2008	A1
20080161713	Leyde et al.	Jul 2008	A1
20080161879	Firlik et al.	Jul 2008	A1
20080161880	Firlik et al.	Jul 2008	A1
20080161881	Firlik et al.	Jul 2008	A1
20080161882	Firlik et al.	Jul 2008	A1
20080183096	Snyder et al.	Jul 2008	A1
20080183097	Leyde et al.	Jul 2008	A1
20080183245	Van Oort et al.	Jul 2008	A1
20080195175	Balzer et al.	Aug 2008	A1
20080200925	Johnson	Aug 2008	A1
20080208013	Zhang et al.	Aug 2008	A1
20080208074	Snyder et al.	Aug 2008	A1
20080208285	Fowler et al.	Aug 2008	A1
20080208291	Leyde et al.	Aug 2008	A1
20080208781	Snyder	Aug 2008	A1
20080215112	Firlik et al.	Sep 2008	A1
20080215114	Stuerzinger et al.	Sep 2008	A1
20080221644	Vallapureddy et al.	Sep 2008	A1
20080234598	Snyder et al.	Sep 2008	A1
20080249591	Gaw et al.	Oct 2008	A1
20080255582	Harris	Oct 2008	A1
20090076567	Fowler et al.	Mar 2009	A1
20090192567	Armstrong et al.	Jul 2009	A1

Foreign Referenced Citations (43)

Number	Date	Country
2339971	Jun 2004	CA
0402683	Dec 1990	EP
0713714	May 1996	EP
1139861	Dec 1999	EP
1070518	Jan 2001	EP
0944411	Apr 2001	EP
1145736	Oct 2001	EP
1483020	Dec 2004	EP
1486232	Dec 2004	EP
1595497	Nov 2005	EP
1120130	Dec 2005	EP
1647300	Apr 2006	EP
1202775	Sep 2006	EP
2026870	Feb 1980	GB
2079610	Jan 1982	GB
9302744	Feb 1993	WO
9417771	Aug 1994	WO
0064336	Nov 2000	WO
0108749	Feb 2001	WO
03085546	Oct 2003	WO
2004036377	Apr 2004	WO
2004064918	Aug 2004	WO
2004069330	Aug 2004	WO
2004071575	Aug 2004	WO
2004075982	Sep 2004	WO
2004112894	Dec 2004	WO
2005007120	Jan 2005	WO
2005007232	Jan 2005	WO
2005053788	Jun 2005	WO
2005028026	Jul 2005	WO
2005067599	Jul 2005	WO
2005101282	Oct 2005	WO
2006014760	Feb 2006	WO
2006019822	Feb 2006	WO
2006050144	May 2006	WO
2006122148	Nov 2006	WO
2007018793	Feb 2007	WO
2007066343	Jun 2007	WO
2007072425	Jun 2007	WO
2007124126	Nov 2007	WO
2007124190	Nov 2007	WO
2007124192	Nov 2007	WO
2007142523	Dec 2007	WO

Non-Patent Literature Citations (40)

Entry
International Application No. PCT/US2013/056209, International Search Report and Written Opinion dated Nov. 19, 2013, 14 pages.
Bachman, D. et al., “Effects of Vagal Volleys and Serotonin on Units of Cingulate Cortex in Monkeys”, Brain Research, vol. 130, 1977, pp. 253-269.
Bohning, D.E., et al.; “Feasibility of Vagus Nerve Stimulation—Synchronized Blood Oxygenation Level-Dependent Functional MRI;” A Joumal of Clinical and Laboratory Research: Investigative Radiology; vol. 36, No. 8 (Aug. 2001 ); pp. 470-479.
Boon, P. et al., “Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy”, Journal of Clinical Neurophysiology, vol. 18, No. 5, 2001, p. 402-407.
Clark, K. et al., “Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat”, Neurobiology of Learning and Memory, vol. 70, Article No. NL983863, 1998, pp. 364-373.
Clark, K. B., et al.; “Enhanced Recognition Memory Following Vagus Nerve Stimulation in Human Subjects;” Nature Neuroscience, vol. 2, No. 1, (Jan. 1999). pp.93-98.
Craig, a.D. (BUD); “Distribution of Trigeminothalamic and Spinothalamic Lamina I Terminations in the Macaque Monkey;” the Journal of Comparative Neurology, vol. 477, pp. 119-148 (2004).
DeGiorgo, Christopher M., et al.; “Vagus Nerve Stimulation: Analysis of Device Parameters in 1 54 Patients During the Long-Term XE5 Study;” Epilepsia, vol. 42, No. 8; pp. 1017-1020 (2001).
Devous, Michael D., et al.; “Effects of Vagus Nerve Stimulation on Regional Cerebral Blood Flow in Treatment- Resistant Depression;” National Institute of Mental Health—42nd Annual NCDEU Meeting: Poster Session II; Poster Abstracts, Jun. 10-13, 2002, 1 page; http://www.nimh.nih.gov/ncdeu/abstracts2002/ncdeu2019.cfm.
Dodrill, PhD., et al.; “Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy;” Epilepsy and Behavior, vol. 2 (2001 ); pp. 46-53.
Fanselow, E.E., at al.; “Reduction of Pentylenetetrazole-Induced Seizure Activity in Awake Rates by Seizure- Triggered Trigeminal Nerve Stimulation;” The Journal of Neuroscience, Nov. 1, 2000; vol. 20/21; pp. 8160-8168.
Fromes, G. A. et al.; “Clinical Utility of On-Demand Magnet use with Vagus Nerve Stimulation;” AES Proceedings, p. 117.
George, M.S., et al .; “Open Trial of VNS Therapy in Severe Anxiety Disorders;” 1 56th American Psychiatric Association Annual Meeting; May 17-22, 2003.
George, M. et al., “Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy”, Society of Biological Psychiatry, vol. 47, 2000, pp. 287-295.
Hallowitz, R. et al., “Effects of Vagal Volleys on Units of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys”, Brain Research, vol. 130, No. 2, Jul. 1977, pp. 271-286.
Harry, J.D., et al.; “Balancing Act: Noise is the Key to Restoring the Body's Sense of Equilibrium;” IEEE Spectrum (Apr. 2005) pp. 37-41.
Henry, T., “Therapeutic Mechanisms of Vague Name Stimulation”, Neurology, vol. 59 (Supp. 4), Sep. 2002, pp. S3-S14.
Henry, T. R., et al.; “Brain Blood-Flow Alterations Induced by Therapeutic Vagus Nerve Stimulation in Partial Epilepsy: I. Acute Effects at High and Low Levels of Stimulation;” Epilepsia vol. 39, No. 9; pp. 984-990 (1998).
King, M .D. , “Effects of Short-Term Vagus Nerve Stimulation (VNS) on FOS Expression in Rat Brain Nuclei” 58th Annual Scientific Convention of the Society of Biological Psychiatry, (May, 2003).
Klapper, MD., et al., “VNS Therapy Shows Potential Benefit in Patients with Migraine and Chronic Daily Headache After 3 to 6 Months of Treatment (Preliminary Results)” 45th Annual Scientific Meeting of the American Headache Society (Jun. 2003).
Koo, B., “EEG Changes with Vagus Nerve Stimulation”, Journal of Clinical Neurophysiology, vol. 18, No. 5, Sep. 2001, pp. 434-441.
Labar, D., “Vagus Nerve Stimulation for 1 Year in 269 patients on Unchanged Antiepilectic Drugs” Seizure vol. 13, (2004) pp. 392-398.
Liebman, K. M. et al.; “Improvement in Cognitive Function After Vagal Nerve Stimulator Implantation;” Epilepsia, vol. 39, Suppl. 6 (1998) 1 page.
Lockard, J. et al., “Feasibility and safety of vagal stimulation in monkey model”, Epilepsia, vol. 31 (Supp. 2), 1990, pp. S20-S26.
Malow, Ba, et al.; “Vagus Nerve Stimulation Reduces Daytime Sleepiness in Epilepsy Patients” Neurology 57 (2001 ) pp. 879-884.
McClintock, P., “Can Noise Actually Boost Brain Power”, Physics World, Jul. 2002, vol. 15, pp. 20-21.
Mori, T. et al., “Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves”, Physical Review Letters, vol. 88, No. 21, 2002, pp. 218101-1-2180101-4.
Rugg-Gunn, F.J., et al.; “Cardiac Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study” www.thelancet.com vol. 364 (2004) pp. 2212-2219.
Rutecki, P.; “Anatomical, Physiological, and Theoretical Basis for the Antiepileptic Effect of Vagus Nerve Stimulation” Epilepsia, vol. 31 Suppl. 2; S1-S6 (1990).
Sahin, M.; et al.; “Improved Nerve Cuff Electrode Recordings with Subthreshold Anodic Currents,” IEEE Transactions on Biomedical Engineering, vol. 45, No. 8 (Aug. 1998) pp. 1 044-1 050.
Schachter, S.C., et al.; “Progress in Epilepsy Research: Vagus Nerve Stimulation,” Epilepsia, vol. 39, No. 7 (1998) pp. 677-686.
Tatum, W.O., et al.; “Ventricular Asystole During Vagus Nerve Stimulation for Epilepsy in Humans” American Academy of Neurologgy (1999) p. 1267 (See also pp. 1 1 17, 1 166, and 1 265).
Tatum, W.O., et al.; “Vagus Nerve Stimulation and Drug Reduction” Neurology, vol. 56, No. 4 (Feb. 2001) pp. 561-563.
Terry, R. et al., “The Implantable Neurocybernetic Prosthesis System”, Pacing and Clinical Electrophysiology, vol. 14, No. 1, Jan. 1991, pp. 86-93.
Tubbs, R. et al., “Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans”, Child's Nervous System, vol. 20, No. 5, May 2004, pp. 309-312.
Valdez-Cruz, A., et al.; “Chronic Stimulation of the Cat Vagus Nerve Effect on Sleep and Behavior” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 26 (2002) pp. 1 13-1 18.
Vonck, K. et al., “The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy—The Current Status”, Journal of Neurophysiology, vol. 18, No. 5, 2001, pp. 394-401.
Ward, H., M.D., et al.; “Treatment-Refractory Obsessive-Compulsive Disorder: Potential Benefit of VNS Therapy” 23rd Annual Conference of the Anxiety Disorders Association of America (2007).
Woodbury, J. et al., “Vagal stimulation reduces the severity of maximal electroshock seizures in intact rats: use of a cuff electrode for stimulating and recording”, Pacing and Clinical Electrophysiology, vol. 14, Jan. 1991, pp. 94-107.
Zabara, J., “Inhibition of Experimental Seizures in Canines by Repetitive Vagal Stimulation”, Epilepsia, vol. 33, No. 6, 1992, pp. 1005-1012.

Related Publications (1)

	Number	Date	Country
	20120330369 A1	Dec 2012	US

Continuation in Parts (2)

	Number	Date	Country
Parent	12020097	Jan 2008	US
Child	13601099		US
Parent	12020195	Jan 2008	US
Child	12020097		US

Contingent cardio-protection for epilepsy patients

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract